<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004598.pub4" GROUP_ID="SYMPT" ID="323303050109390523" MERGED_FROM="" MODIFIED="2016-07-28 16:15:42 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="72" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2016-07-28 16:15:41 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2008-09-24 14:26:37 +0100" MODIFIED_BY="Laila Tyrrell">Local anaesthetic sympathetic blockade for complex regional pain syndrome</TITLE>
<CONTACT>
<PERSON ID="10472083387152902171110602182329" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tasha</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Stanton</LAST_NAME>
<SUFFIX/>
<POSITION>Postdoctoral Research Fellow</POSITION>
<EMAIL_1>t.stanton@neura.edu.au</EMAIL_1>
<EMAIL_2>tasha.stanton@unisa.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE>+614 4915 1463</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>The Sansom Institute for Health Research, School of Health Sciences</DEPARTMENT>
<ORGANISATION>University of South Australia, GPO Box 2471</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Adelaide</CITY>
<ZIP>5001</ZIP>
<REGION>South Australia</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+612 9399 1273</PHONE_1>
<PHONE_2>+618 8302 2090</PHONE_2>
<FAX_1>+612 9399 1082</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-07-28 14:53:11 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="573BBDAF82E26AA201E3BD51D3F1E7E0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Neil</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>O'Connell</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Senior Lecturer</POSITION>
<EMAIL_1>neil.oconnell@brunel.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Sciences/Health Economics Research Group, Institute of Environment, Health and Societies</DEPARTMENT>
<ORGANISATION>Brunel University</ORGANISATION>
<ADDRESS_1>Kingston Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Uxbridge</CITY>
<ZIP>UB8 3PH</ZIP>
<REGION>Middlesex</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1895 268814</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1895 269853</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="55382108175837620829110303125451" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Benedict</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Wand</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>benedict.wand@nd.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Physiotherapy</DEPARTMENT>
<ORGANISATION>The University of Notre Dame Australia</ORGANISATION>
<ADDRESS_1>19 Mouat Street (PO Box 1225)</ADDRESS_1>
<ADDRESS_2/>
<CITY>Fremantle</CITY>
<ZIP>6959</ZIP>
<REGION>West Australia</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 8 9433 0589</PHONE_1>
<PHONE_2/>
<FAX_1>+61 8 9433</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1405151007003390486342243490029" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gibson</LAST_NAME>
<SUFFIX/>
<POSITION>Acting Dean and Senior Lecturer</POSITION>
<EMAIL_1>william.gibson@nd.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Physiotherapy</DEPARTMENT>
<ORGANISATION>The University of Notre Dame Australia</ORGANISATION>
<ADDRESS_1>19 Mouat Street (PO Box 1225)</ADDRESS_1>
<ADDRESS_2/>
<CITY>Fremantle</CITY>
<ZIP>6959</ZIP>
<REGION>Western Australia</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 8 9433 0589</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15608" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Daniel</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Carr</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Professor and Director</POSITION>
<EMAIL_1>daniel.carr@tufts.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pain Research, Education and Policy (PREP) Program, Department of Public Health and Community Medicine</DEPARTMENT>
<ORGANISATION>Tufts University School of Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP/>
<REGION>Massachusetts</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 617 636 9710</PHONE_1>
<PHONE_2/>
<FAX_1>+1 617 636 9709</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="68067773075488711434110602182606" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Frank</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Birklein</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>Frank.Birklein@unimedizin-mainz.de</EMAIL_1>
<EMAIL_2>frank.birklein@unimedizin-mainz.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University Medical Centre</DEPARTMENT>
<ORGANISATION>Johannes Gutenberg University</ORGANISATION>
<ADDRESS_1>Langenbeck Street 1</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mainz</CITY>
<ZIP>D-55131</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 6131 173270</PHONE_1>
<PHONE_2/>
<FAX_1>+49 6131 175625</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10472083387152902171110602182329" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tasha</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Stanton</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>t.stanton@neura.edu.au</EMAIL_1>
<EMAIL_2>tasha.stanton@unisa.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE>+614 4915 1463</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Neuroscience Research Australia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Randwick</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-07-28 16:15:41 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;Anna E: Reviews can be 'stabilised' (i.e. the next update postponed) if no new evidence is likely. Please discuss with PaPaS re. postponing the update beyond the normal two years if applicable, either permanently, or with a given timeframe of 5 or 10 years.&lt;/p&gt;&lt;p&gt;Suggested wording:&lt;/p&gt;&lt;p&gt;&amp;quot;A new search within two years is not likely to identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. [The review will be re-assessed for updating in five years.] If appropriate, we will update the review [before this date] if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.&amp;quot;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Tasha: I think we are happy to stablise this review for 5 years as it is unlikely that sufficient relevant studies would be published that would change the review's conclusions. Anna - are we meant to write the above text as a &amp;quot;what's New&amp;quot; note?&lt;/p&gt;&lt;p&gt;&lt;b&gt;AE Mar: thanks, Tasha. EDITOR please confirm this is OK.&lt;/b&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-07-15 11:21:23 +0100" NOTES_MODIFIED_BY="Neil O'Connell">
<UP_TO_DATE>
<DATE DAY="16" MONTH="9" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="9" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-07-28 14:53:51 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-07-28 14:53:51 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="28" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-07-28 14:53:36 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-28 14:53:34 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="7" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>The conclusions of the review remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-07-28 14:53:36 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="16" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>This updated review used refined exclusion criteria (exclude studies with follow-up of &lt;48hrs) (see <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>). This resulted in the exclusion of 4 studies from this update that had been included in previous versions of this review (<LINK REF="STD-Meier-2009" TYPE="STUDY">Meier 2009</LINK>; <LINK REF="STD-Raja-1991" TYPE="STUDY">Raja 1991</LINK>; <LINK REF="STD-Verdugo-1995" TYPE="STUDY">Verdugo 1995</LINK>; <LINK REF="STD-Wehnert-2002" TYPE="STUDY">Wehnert 2002</LINK>). We also updated the data analysis that included consideration of the minimally important difference (as per OMERACT 12 group recommendations) and evaluation of the quality of evidence using the GRADE approach.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-07 15:34:31 +0000" MODIFIED_BY="Anna Erskine">
<DATE DAY="26" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>This updated review used an expanded search strategy, updated Risk of Bias assessment, and updated inclusion criteria. These changes resulted in inclusion of 10 additional studies compared with the initial review (n = 363 additional participants); two studies compared LASB to a placebo/inert treatment (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>), the remaining nine studies compared LASB with an active treatment [<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Meier-2009" TYPE="STUDY">Meier 2009</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Raja-1991" TYPE="STUDY">Raja 1991</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Wehnert-2002" TYPE="STUDY">Wehnert 2002</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>) or investigated the effect of adding LASB to an active treatment (<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>). Despite these methodological updates and inclusion of new studies, the conclusions of the review remain unchanged; there is a dearth of published evidence for LASB and the available evidence suggests lack of efficacy. Readers of the original review would benefit from reading this update as new evidence is provided for treatment comparisons between LASB and other active interventions (for example, intravenous regional anesthesia).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-03-07 15:34:35 +0000" MODIFIED_BY="Anna Erskine">
<DATE DAY="26" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Despite methodological updates and inclusion of new studies, the conclusions of the review remain unchanged; there is a dearth of published evidence for LASB and the available evidence suggests lack of efficacy.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:08:47 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="3" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>The following changes have been made to the methodology of the protocol. We have made them all to bring the protocol up to date with the current PaPaS author guidelines:</P>
<P>We have chosen to adopt a modified version of the Cochrane ROB tool with additional criteria added in response to the recommendations of Moore et al. (2010). As such we have added 2 additional criteria &#8220;Size&#8221; and &#8220;Duration&#8221; using the thresholds for judgement suggested by <LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>. We have not added the &#8220;Outcome&#8221; criteria as this is covered already by our choice of primary outcome measures.</P>
<P>We have rewritten the data synthesis/ analysis sections to fit the current RevMan headings. We now specify that we will calculate Risk Ratio for achieving a moderately important benefit (30% or more) or a substantially important benefit (50% or more) and have specified time windows for short, medium and long term follow up. We suggest the following preplanned subgroup analyses where adequate data allow: CRPS I vs II, Adults vs children and single vs continuous blockade.</P>
<P>We have added a planned sensitivity analyses, where data are sufficient, to allow testing of the effect of including/ excluding studies whose risk of bias is unclear or high.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-02-12 12:41:23 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>The Background section has been substantively rewritten to fit the headings now suggested in RevMan.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:08:52 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="22" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Searching other resources - unpublished studies: We have expanded this search strategy to also include clinical and controlled trial registers, such as http://www.controlledtrials.com/, the Australian New Zealand Clinical Trials Register (http://www.anzctr.org.au/), and a European Clinical Trials Register (<A HREF="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</A>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:09:03 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="21" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>We have added new search terms to the search strategy that will make it more sensitive and conforms to updates in treatment (for example, Botox now being used for sympathetic chain blockades). Also attached is an updated search strategy for Medline, created in collaboration with Jane Hayes from PaPaS.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:08:55 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="21" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Methods: selection of studies. Two independent reviewers will screen the titles and abstracts of the search results in order to determine which full text articles to retrieve. This is changed from one reviewer.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-02-12 12:41:56 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Addition of new criteria for considering studies for this review (Types of interventions).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:09:08 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="21" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>We have inserted a new Table (under other Tables) that provides the new Budapest criteria for diagnosing CRPS.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:08:57 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="21" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Addition of new criteria for considering studies for this review (Types of participants). </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-26 13:09:10 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="9" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-09 18:04:40 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Saltonstall Foundation</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Javeriana University School of Medicine</NAME>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-28 14:54:36 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2016-06-20 11:37:13 +0100" MODIFIED_BY="[Empty name]">Local anaesthetic sympathetic blockade for complex regional pain syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>
<B>Background</B>
</P>
<P>Local anaesthetic sympathetic blockade (LASB) is a common treatment for complex regional pain syndrome (CRPS). It involves blocking the activity of sympathetic nerves alongside the spine. The sympathetic nervous system mainly controls unconscious actions such as heart rate, blood flow, and perspiration. The injection of a local anaesthetic drug around the nerves temporarily blocks the function of the nerves. This updated review aimed to summarise the available evidence regarding whether LASB is effective at reducing pain in CRPS, how long any pain relief might last, and whether LASB is safe.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>In September 2015, we found a limited number of small trials, all of which had design flaws. We did not find evidence that LASB was better than placebo in reducing pain, or that it provided additional pain relief when added to rehabilitation. While a number of small studies compared LASB to other treatments, most did not find that LASB was better. One small study found that injecting the thoracic (upper back) sympathetic nerves with local anaesthetic and steroid was better than injecting the same drugs just under the skin at one-year follow-up, but the study may have been prone to bias. Only six studies reported on the type and amount of side effects. These studies reported only minor side effects, but since some studies did not report this information we can draw no firm conclusions about the safety of LASB. The evidence was mostly of low or very low quality.</P>
<P>Overall, the evidence is limited, conflicting, and of low quality. While we cannot draw strong conclusions, the existing evidence is not encouraging.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<ABS_BACKGROUND MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine">
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews, 2005, Issue 4 (and last updated in the Cochrane Database of Systematic Reviews, 2013 issue 8), on local anaesthetic blockade (LASB) of the sympathetic chain to treat people with complex regional pain syndrome (CRPS).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-06-21 09:00:41 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy of LASB for the treatment of pain in CRPS and to evaluate the incidence of adverse effects of the procedure.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 9), MEDLINE (Ovid), EMBASE (Ovid), LILACS (Birme), conference abstracts of the World Congresses of the International Association for the Study of Pain, and various clinical trial registers up to September 2015. We also searched bibliographies from retrieved articles for additional studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We considered randomised controlled trials (RCTs) that evaluated the effect of sympathetic blockade with local anaesthetics in children or adults with CRPS compared to placebo, no treatment, or alternative treatments.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine">
<P>We used standard methodological procedures expected by Cochrane. The outcomes of interest were reduction in pain intensity, the proportion who achieved moderate or substantial pain relief, the duration of pain relief, and the presence of adverse effects in each treatment arm. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) and created a 'Summary of findings' table.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We included an additional four studies (N = 154) in this update. For this update, we excluded studies that did not follow up patients for more than 48 hours. As a result, we excluded four studies from the previous review in this update. Overall we included 12 studies (N = 461), all of which we judged to be at high or unclear risk of bias. Overall, the quality of evidence was low to very low, downgraded due to limitations, inconsistency, imprecision, indirectness, or a combination of these.</P>
<P>Two small studies compared LASB to placebo/sham (N = 32). They did not demonstrate significant short-term benefit for LASB for pain intensity (moderate quality evidence).</P>
<P>One small study (N = 36) at high risk of bias compared thoracic sympathetic block with corticosteroid and local anaesthetic versus injection of the same agents into the subcutaneous space, reporting statistically significant and clinically important differences in pain intensity at one-year follow-up but not at short term follow-up (very low quality evidence).</P>
<P>Of two studies that investigated LASB as an addition to rehabilitation treatment, the only study that reported pain outcomes demonstrated no additional benefit from LASB (very low quality evidence).</P>
<P>Eight small randomised studies compared sympathetic blockade to various other active interventions. Most studies found no difference in pain outcomes between sympathetic block versus other active treatments (low to very low quality evidence).</P>
<P>One small study compared ultrasound-guided LASB with non-guided LASB and found no clinically important difference in pain outcomes (very low quality evidence).</P>
<P>Six studies reported adverse events, all with minor effects reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>This update's results are similar to the previous versions of this systematic review, and the main conclusions are unchanged. There remains a scarcity of published evidence and a lack of high quality evidence to support or refute the use of local anaesthetic sympathetic blockade for CRPS. From the existing evidence, it is not possible to draw firm conclusions regarding the efficacy or safety of this intervention, but the limited data available do not suggest that LASB is effective for reducing pain in CRPS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-14 16:03:13 +0100" MODIFIED_BY="Anna Erskine">
<BACKGROUND MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews, 2005, Issue 4 (and last updated in the Cochrane Database of Systematic Reviews, 2013 Issue 8), on local anaesthetic sympathetic blockade for complex regional pain syndrome.</P>
<CONDITION MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>Complex regional pain syndrome (CRPS) is an umbrella term for a variety of clinical presentations characterised by chronic persistent pain that is disproportionate to any preceding injury (if any) and that is not restricted anatomically to the distribution of a specific peripheral nerve (<LINK REF="REF-Bruehl-2010" TYPE="REFERENCE">Bruehl 2010</LINK>). The International Association for the Study of Pain (IASP) introduced the diagnostic label of CRPS in the 1990s (<LINK REF="REF-Merskey-1994" TYPE="REFERENCE">Merskey 1994</LINK>), and since then, others have updated it in an attempt to improve its specificity (<LINK REF="REF-Harden-2006" TYPE="REFERENCE">Harden 2006</LINK>; <LINK REF="REF-Harden-2010" TYPE="REFERENCE">Harden 2010</LINK>). We present these modified diagnostic criteria (the 'Budapest criteria') in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. The term CRPS encompasses a variety of earlier diagnostic terms, including reflex sympathetic dystrophy (RSD), reflex neurovascular dystrophy, Sudeck's atrophy, causalgia, and algodystrophy/algoneurodystrophy (<LINK REF="REF-Stanton_x002d_Hicks-1995" TYPE="REFERENCE">Stanton-Hicks 1995</LINK>). CRPS can be classified into two subtypes: CRPS-I, in which there is no identified peripheral nerve injury, and CRPS-II, where symptoms are associated with a definable nerve lesion (<LINK REF="REF-Harden-2006" TYPE="REFERENCE">Harden 2006</LINK>). This distinction is not always easily made (<LINK REF="REF-Harden-2006" TYPE="REFERENCE">Harden 2006</LINK>). Both subtypes of CRPS are characterised by severe pain that is disproportionate to the inciting event, most commonly affecting the hand or foot but sometimes spreading to other body regions (<LINK REF="REF-Stanton_x002d_Hicks-2002" TYPE="REFERENCE">Stanton-Hicks 2002</LINK>; <LINK REF="REF-Van-Rijn-2011" TYPE="REFERENCE">Van Rijn 2011</LINK>). Additionally CRPS presents with some or all of the following symptoms in the affected body parts: sensory disturbances; temperature changes; abnormal patterns of perspiration; swelling/oedema; reduced joint range of motion; movement abnormalities such as weakness, tremor, or dystonia; trophic changes such as skin atrophy, altered hair and nail growth, or localised osteoporotic changes (<LINK REF="REF-Bruehl-2010" TYPE="REFERENCE">Bruehl 2010</LINK>; <LINK REF="REF-De-Mos-2009" TYPE="REFERENCE">De Mos 2009</LINK>; <LINK REF="REF-Shipton-2009" TYPE="REFERENCE">Shipton 2009</LINK>); and alterations in body perception (<LINK REF="REF-Lewis-2007" TYPE="REFERENCE">Lewis 2007</LINK>; <LINK REF="REF-Lotze-2007" TYPE="REFERENCE">Lotze 2007</LINK>; <LINK REF="REF-Moseley-2006" TYPE="REFERENCE">Moseley 2006</LINK>). CRPS occurs most commonly following wrist fracture and subsequent immobilisation. However, cases can potentially occur after relatively minor trauma and may even occur spontaneously, albeit rarely (<LINK REF="REF-De-Mos-2007" TYPE="REFERENCE">De Mos 2007</LINK>; <LINK REF="REF-De-Mos-2008" TYPE="REFERENCE">De Mos 2008</LINK>; <LINK REF="REF-Sandroni-2003" TYPE="REFERENCE">Sandroni 2003</LINK>). The underlying pathophysiological mechanisms of CRPS are incompletely understood, although there is growing consensus that it is primarily a disorder of the nervous system. Research has identified abnormalities in the tissues of the affected area and the peripheral and central nervous systems (<LINK REF="REF-J_x00e4_nig-2003" TYPE="REFERENCE">Jänig 2003</LINK>; <LINK REF="REF-Marinus-2011" TYPE="REFERENCE">Marinus 2011</LINK>). These include signs of increased neurogenic inflammation (<LINK REF="REF-Birklein-2001" TYPE="REFERENCE">Birklein 2001</LINK>; <LINK REF="REF-Schinkel-2006" TYPE="REFERENCE">Schinkel 2006</LINK>; <LINK REF="REF-Schmelz-2001" TYPE="REFERENCE">Schmelz 2001</LINK>), an altered local immune response (<LINK REF="REF-Birklein-2014" TYPE="REFERENCE">Birklein 2014</LINK>; <LINK REF="REF-Tan-2005" TYPE="REFERENCE">Tan 2005</LINK>), altered activity in the sympathetic nervous system (SNS) (<LINK REF="REF-Drummond-2004" TYPE="REFERENCE">Drummond 2004</LINK>; <LINK REF="REF-Niehof-2006" TYPE="REFERENCE">Niehof 2006</LINK>), increased sensitivity to normal SNS activity (<LINK REF="REF-Albrecht-2006" TYPE="REFERENCE">Albrecht 2006</LINK>; <LINK REF="REF-Ali-2000" TYPE="REFERENCE">Ali 2000</LINK>; <LINK REF="REF-Drummond-2001" TYPE="REFERENCE">Drummond 2001</LINK>), and local tissue hypoxia (<LINK REF="REF-Birklein-2000" TYPE="REFERENCE">Birklein 2000</LINK>; <LINK REF="REF-Koban-2003" TYPE="REFERENCE">Koban 2003</LINK>). Studies have also demonstrated changes in the brain in CRPS (<LINK REF="REF-Swart-2009" TYPE="REFERENCE">Swart 2009</LINK>), including alterations of the cortical (higher brain) representation of the affected body part (<LINK REF="REF-Maih_x00f6_fner-2004" TYPE="REFERENCE">Maihöfner 2004</LINK>; <LINK REF="REF-Pleger-2006" TYPE="REFERENCE">Pleger 2006</LINK>), localised reductions in grey matter density and connectivity (<LINK REF="REF-Geha-2008" TYPE="REFERENCE">Geha 2008</LINK>), and altered inhibitory control (<LINK REF="REF-Schwenkreis-2003" TYPE="REFERENCE">Schwenkreis 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Sympathetic blockade includes procedures that aim to temporarily impede the local function of the sympathetic nervous system. Usually an anaesthesiologist performs the procedure, injecting local anaesthetic directly into sympathetic neural structures that serve the affected limb(s) such as the stellate ganglion or the lumbar sympathetic chain (<LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006</LINK>). Radiologic guidance such as fluoroscopy or computerised tomography (CT) scan often ensures the accuracy of needle tip placement, and successful blockade is often monitored by direct (e.g., galvanic skin response) or indirect (increase in blood flow to the extremity or increase in temperature) assessment (<LINK REF="REF-Breivik-2009" TYPE="REFERENCE">Breivik 2009</LINK>). This approach is distinct from the injection of neurolytic agents in an effort to destroy sympathetic nerves. LASBs are also commonly called stellate ganglion blockades (SGB) or, when performed in the lower body, lumbar sympathetic blockades (LSB).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>People with persistent pain following nerve injury have long been observed to have abnormalities of autonomic nervous system function in the affected limb (temperature, blood flow, sweating) and abnormal skin texture or hair and nail growth attributed, at least in part, to local autonomic dysfunction (<LINK REF="REF-Bruehl-2010" TYPE="REFERENCE">Bruehl 2010</LINK>; <LINK REF="REF-De-Mos-2009" TYPE="REFERENCE">De Mos 2009</LINK>). Early uncontrolled observations of persistent improvement in signs and symptoms following local anaesthetic sympathetic blockade in people with what is now termed CRPS suggested that excessive sympathetic activity provoked or perpetuated this type of persistent pain (<LINK REF="REF-Campbell-1996" TYPE="REFERENCE">Campbell 1996</LINK>). However, recent evidence regarding adrenaline content in venous effluents from affected limbs has not supported this hypothesis and suggests instead that any benefit of sympathetic blockade in CRPS may reflect transient reversal of a heightened local sensitivity to adrenaline (<LINK REF="REF-Binder-2009" TYPE="REFERENCE">Binder 2009</LINK>). These clinical impressions of persistent benefit from transient local anaesthetic sympathetic blockade in CRPS, reinforced by similar longstanding impressions of prolonged benefit after temporary local anaesthetics blockade in peripheral neuralgias, led to the incorporation of sympathetic block into current consensus treatment algorithms for CRPS (<LINK REF="REF-Carr-2011" TYPE="REFERENCE">Carr 2011</LINK>), although doubt remains over the contribution of the sympathetic nervous system to pain and the concept of sympathetically maintained pain in CRPS (<LINK REF="REF-Harden-2013" TYPE="REFERENCE">Harden 2013</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>Despite preclinical evidence that suggests the sympathetic nervous system is involved in the pathophysiology of CRPS, there is debate surrounding the contribution of the sympathetic nervous system to the clinical syndrome (<LINK REF="REF-Ochoa-1995" TYPE="REFERENCE">Ochoa 1995</LINK>; <LINK REF="REF-Schott-1995" TYPE="REFERENCE">Schott 1995</LINK>; <LINK REF="REF-Verdugo-1994a" TYPE="REFERENCE">Verdugo 1994a</LINK>; <LINK REF="REF-Verdugo-1994b" TYPE="REFERENCE">Verdugo 1994b</LINK>). The value of blocking the sympathetic nervous system is also disputed (<LINK REF="REF-Fine-1994" TYPE="REFERENCE">Fine 1994</LINK>; <LINK REF="REF-Hogan-1997" TYPE="REFERENCE">Hogan 1997</LINK>; <LINK REF="REF-Jadad-1995" TYPE="REFERENCE">Jadad 1995</LINK>; <LINK REF="REF-Verdugo-1994a" TYPE="REFERENCE">Verdugo 1994a</LINK>). It is therefore important to evaluate the efficacy of sympathetic blockade with local anaesthetic in the treatment of CRPS. A meta-analysis of the effect of sympathetic blockade with local anaesthetics in people with CRPS reported that up to 44% of those subjected to sympathetic blockade would be expected to have no pain relief. Due to the lack of randomised controlled trials, investigators obtained this estimate from pooling the results of observational studies (<LINK REF="REF-Cepeda-2002" TYPE="REFERENCE">Cepeda 2002</LINK>). Moreover, the review only evaluated English-language studies, and it could have overlooked relevant RCTs. Hence, to overcome this limitation, we decided to perform a systematic review of the literature with no language restriction to determine both the efficacy and safety of sympathetic blockade with local anaesthetics to alleviate pain in people with CRPS.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-06-21 09:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy of LASB for the treatment of pain in CRPS and to evaluate the incidence of adverse effects of the procedure.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<SELECTION_CRITERIA MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<CRIT_STUDIES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We considered randomised controlled trials (RCTs). As blinding of sympathetic block is not always possible, we included trials that were either double-blind, single-blind, or open. We included studies that compared LASB with placebo interventions, no treatment, or alternative interventions. We also included studies that investigated the effect of adding LASB to other interventions.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We included studies that evaluated the effect of sympathetic blockade with local anaesthetics to treat CRPS in children or adults. We included studies even if the authors did not describe the constellation of symptoms necessary to diagnose CRPS and stated only that "patients with RSD/CRPS were included". We took this approach to avoid excluding any of the relatively few RCTs of this intervention. We placed no restrictions regarding the number of participants recruited to trials.</P>
<P>We excluded trials that evaluated sympathetic blockade for other pain syndromes such as radiculopathy, herpes zoster, postherpetic neuralgia, fibromyalgia, or phantom pain.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We included studies that evaluated selective sympathetic blockade with local anaesthetics. We excluded studies that only evaluated somatic nerve blocks or studies that evaluated the effect of local anaesthetics or sympatholytic drugs administered orally, intravenously, or epidurally. We excluded studies that reported the results of combined sympatholytic therapies, such as surgical sympathectomy or guanethidine intravenous regional block plus local anaesthetic blockade of the sympathetic chain. We also excluded studies of ganglionide local opioid analgesia (GLOA), a technique in which clinicians locally inject opioids such as buprenorphine into the stellate ganglion, because this procedure does not block sympathetic activity.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>The outcomes of interest were pain intensity levels, duration of pain relief. and adverse events. For this update, we excluded studies that had only immediate follow-up data (&#8804; 48 h), because this information provides little clinically relevant information about the effectiveness of this treatment. We applied this new criterion to studies that had been included in previous updates of this review.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>For this update, we used identical search strategies to that of our 2013 review update. For the search strategies, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the Cochrane Central Register of Controlled Trials (CENTRAL), <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for MEDLINE, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for EMBASE, and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> for LILACS.</P>
<P>We performed the search for the original review from November 2003 to January 2004 updated it on 17 November 2011 and 22 November 2012 (2013 update). The present update encompasses searches run from 22 November 2012 to 16 September 2015.</P>
<P>We evaluated non-English language papers for inclusion.</P>
<P>For the 2016 update, we did not search the Cochrane Pain, Palliative and Supportive Care Group Specialised Register, as it is no longer updated.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We searched the following databases for the update of this review.</P>
<UL>
<LI>CENTRAL (<I>The Cochrane Library </I>2015, Issue 9).</LI>
<LI>MEDLINE (Ovid) (1966 to September 2015).</LI>
<LI>EMBASE (Ovid) (1974 to September 2015).</LI>
<LI>LILACS (Birme) (1982 to September 2015).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We searched the bibliographies of retrieved articles for additional studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unpublished studies</HEADING>
<P>In order to minimise the impact of publication bias, we reviewed conference abstracts of the World Congresses of the International Association for the Study of Pain from 1995 up to 2014. For this update, we expanded the search of the original review by also searching relevant clinical trial registers (from inception) for upcoming trials. We searched the following clinical trial registers: the controlled trials register (15 October 2015; <A HREF="http://www.controlled-trials.com/">www.controlled-trials.com/</A>), the United States National Institute of Health service ClinicalTrials.gov (15 October 2015; <A HREF="https://www.clinicaltrials.gov/">www.clinicaltrials.gov/</A>); the Australian New Zealand Clinical trials register (15 October 2015; <A HREF="http://www.anzctr.org.au/">www.anzctr.org.au/</A>), and the European Clinical Trials Register (7 December 2012; <A HREF="https://www.clinicaltrialsregister.eu/">www.clinicaltrialsregister.eu/</A>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Personal contact</HEADING>
<P>We attempted to communicate with authors if we needed additional information that was not provided in the trial report. In addition, we provided the reference list of included studies to experts in the field to determine if any additional references were appropriate for the review.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<STUDY_SELECTION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Two review authors independently read each of the titles and abstracts of the reports identified by the search and discarded narrative reviews, case series, and case reports. If there was no abstract, we retrieved the full-text report. If there was disagreement, the authors met to reach consensus, consulting an independent third review author if necessary. We retrieved in full all abstracts and reports that made reference to a trial of sympathetic blockade with local anaesthetics . Two review authors then independently assessed the full-text articles. We did not anonymise the reports for the assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Two review authors independently extracted the data. If there was disagreement, they met to reach consensus, consulting an independent third review author if necessary. We extracted the following data from each study.</P>
<OL>
<LI>Study details: study design (parallel or cross-over), method of randomisation, presence or absence of blinding.</LI>
<LI>Demographic characteristics: age, sex, number of participants recruited, number of study withdrawals or drop-outs, if any.</LI>
<LI>Participant clinical characteristics: duration of pain before sympathetic block, site of pain (arm, leg, mixed, or other such as facial).</LI>
<LI>Type of noxious initiating event (if known): surgery, fracture, crush injury, projectile, or stab injury.</LI>
<LI>Type of tissue injured: nerve, soft tissue, bone.</LI>
<LI>Presence of medico-legal factors that may influence the experience of pain and the outcomes of therapeutic interventions.</LI>
<LI>Concomitant treatments that may affect outcome: antidepressants, physical therapy, etc.</LI>
<LI>Treatment characteristics: site of sympathetic block (cervical or lumbar), type of local anaesthetic used (including concentration and volume), evaluation of the technical adequacy of the block, duration of follow-up, duration of the pain relief, number of blocks performed, method of pain assessment, and presence of complications or adverse effects.</LI>
<LI>Information on postprocedure analgesic requirements.</LI>
<LI>Information on conflicts of interest and statements of study support.</LI>
</OL>
<P>If authors reported pain intensity using a visual analogue scale or numeric rating scale, we extracted the mean and standard deviation of pain intensity in each study arm. If authors reported pain relief, we extracted the proportion of participants in each category of pain relief.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>We used a modified version of the Cochrane 'Risk of bias' tool with additional domains added in response to the recommendations of <LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>. On this basis we added two domains, 'size' and 'duration', using the thresholds for judgement suggested by <LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>. We have not added the 'outcome' domain as this is covered already by our choice of primary outcome measures. Thus in addition to the standard items in the 'Risk of bias' tool:</P>
<UL>
<LI>selection bias (random sequence generation, allocation concealment);</LI>
<LI>performance bias (blinding of participants and personnel);</LI>
<LI>detection bias (blinding of outcome assessment);</LI>
<LI>attrition bias (incomplete outcome data; consideration of analysis methods, e.g., imputation method);</LI>
<LI>reporting bias (selective reporting); and</LI>
<LI>other sources of bias;</LI>
</UL>
<P>We also assessed the following domains as recommended by <LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>.</P>
<UL>
<LI>Size (rating studies with fewer than 50 participants per arm as being at high risk of bias, those with between 50 and 199 participants per arm as being at unclear risk of bias, and 200 or more participants per arm as being at low risk of bias).</LI>
<LI>Duration (rating studies with follow-up of two weeks as being at high risk of bias, two to seven weeks as being at unclear risk of bias and eight weeks or longer as being at low risk of bias).</LI>
</UL>
<P>Two review authors completed the 'Risk of bias' assessment for each included study independently. If there was disagreement, the authors met to reach consensus, consulting an independent third review author if necessary.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>We compared the post-treatment pain intensity scores between the trial arms. Where possible, we calculated the proportion of participants with a specific degree of pain relief and converted it into dichotomous information to yield the number of participants who obtained a moderately important benefit (30% pain relief) or a substantially important benefit (50% or more pain relief) as defined by the IMMPACT recommendations (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>). We planned to calculate the risk ratio (RR) as the measure of treatment effect and used this to calculate the number needed to treat for an additional beneficial outcome (NNTB) for 30% and 50% pain relief. We also collected data on the duration of pain relief postintervention where available.</P>
<P>For this update, we used the OMERACT 12 group's recommendations for minimally important difference for pain outcomes reported on a continuous scale (<LINK REF="REF-Busse-2015" TYPE="REFERENCE">Busse 2015</LINK>). They recommend 10 mm on a 0-100 mm visual analogue scale (VAS) as the threshold for minimal importance for average between-group change. They highlight that should be interpreted with caution as estimates that fall closely below this point may still reflect a treatment that benefits a considerable number of patients. We used this threshold but interpreted it cautiously.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine">
<P>No unit of analysis issues arose since we were unable to conduct a meta-analysis due to insufficient data.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-03-07 15:47:35 +0000" MODIFIED_BY="Anna Erskine">
<P>Where insufficient data were presented to enter a study into the meta-analysis, we contacted study authors to request access to the missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We planned to assess heterogeneity and its impact using the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where significant heterogeneity (P &lt; 0.1) was present, we planned to conduct subgroup analyses. Preplanned comparisons included CRPS-I versus CRPS-II, children versus adults, and continuous versus single block. However, no meta-analysis was possible.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We considered the possible influence of publication/small study biases on review findings. For studies that utilised dichotomised outcomes, where possible, we planned to test for the possible influence of publication bias on each outcome by estimating the number of participants in studies with zero effect required to change the NNTB to an unacceptably high level (defined as an NNTB of 10) as outlined by <LINK REF="REF-Moore-2008" TYPE="REFERENCE">Moore 2008</LINK>.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We pooled results where adequate data supported this, using Review Manager 5 software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). Separate preplanned meta-analyses included sympathetic blockade versus sham/placebo procedure and sympathetic blockade versus no treatment or usual care. We used a random-effects model to combine the studies. We considered separate meta-analyses for short-term (up to two weeks postintervention), mid-term (more than two to less than seven weeks postintervention) and long-term (seven weeks or longer postintervention) outcomes where we identified adequate data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of quality of available evidence</HEADING>
<P>For this update we used the GRADE approach to assess the quality of evidence (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>). Two reviewers independently applied the GRADE criteria to each key comparison. If there was disagreement, the authors met to reach consensus, consulting an independent third review if necessary. We present a summary of our judgements for each comparison in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
<P>To ensure consistency of GRADE judgements, we applied the following criteria to each domain equally for all key comparisons of the primary outcome.</P>
<UL>
<LI>Limitations of studies: downgrade once if more than 25% of participants were from studies classified as being at a high risk of bias across any domain, excluding the 'study size' domain as this is accounted for in the assessment of imprecision.</LI>
<LI>Inconsistency: downgrade once if heterogeneity is statistically significant and the I<SUP>2</SUP> value is more than 40%. When a meta-analysis was not performed we downgraded once if trials did not show effects in the same direction.</LI>
<LI>Indirectness: downgrade once if more than 50% of the participants were outside the target group.</LI>
<LI>Imprecision: downgrade once if fewer than 400 participants for continuous data and fewer than 300 events for dichotomous data.</LI>
<LI>Publication bias: downgrade once where there is direct evidence of publication bias or if estimates of effect based on small scale, industry-sponsored studies raising a high index of suspicion of publication bias.</LI>
</UL>
<P>Two review authors (NEO, BMW) judged whether these factors were present. We considered single studies to be inconsistent and imprecise, unless more than 400 participants were randomised for continuous outcomes or more than 300 for dichotomous outcomes. We applied the following definitions of the quality of the evidence (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>).</P>
<UL>
<LI>High quality: We are very confident that the true effect lies close to that of the estimate of the effect.</LI>
<LI>Moderate quality: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</LI>
<LI>Low quality: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.</LI>
<LI>Very low quality: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">'Summary of findings' table</HEADING>
<P>We included a 'Summary of findings' table to present the main findings in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcome pain intensity, hand pain, and duration of pain relief.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We assessed heterogeneity and its impact using the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where significant heterogeneity (P &lt; 0.1) was present we planned to conduct subgroup analyses. Preplanned comparisons included CRPS-I versus CRPS-II, children versus adults, and repeated versus single blocks.</P>
<P>Where possible we used the proportion of people with adverse side effects in each treatment group to calculate the number needed to treat for an additional harmful outcome (NNTH).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-03-07 15:47:54 +0000" MODIFIED_BY="Anna Erskine">
<P>When sufficient data were available, we conducted sensitivity analyses on the effect of including/excluding studies classified as being at unclear or high risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-14 16:03:13 +0100" MODIFIED_BY="Anna Erskine">
<STUDY_DESCRIPTION MODIFIED="2016-07-14 15:56:54 +0100" MODIFIED_BY="Anna Erskine">
<SEARCH_RESULTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>The previous update of this review included twelve studies (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Meier-2009" TYPE="STUDY">Meier 2009</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>, <LINK REF="STD-Raja-1991" TYPE="STUDY">Raja 1991</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Verdugo-1995" TYPE="STUDY">Verdugo 1995</LINK>, <LINK REF="STD-Wehnert-2002" TYPE="STUDY">Wehnert 2002</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>; combined N = 386). For this update, we included an additional four studies (<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>; combined N = 154]). As our modified criteria excluded studies with follow-up of 48 hours or less, we excluded four studies from this update that had been included in previous versions of this review (<LINK REF="STD-Meier-2009" TYPE="STUDY">Meier 2009</LINK>; <LINK REF="STD-Raja-1991" TYPE="STUDY">Raja 1991</LINK>; <LINK REF="STD-Verdugo-1995" TYPE="STUDY">Verdugo 1995</LINK>; <LINK REF="STD-Wehnert-2002" TYPE="STUDY">Wehnert 2002</LINK>; combined N = 79). Overall, we included 12 studies with 461 participants in this update.</P>
<P>One new study is awaiting classification, as it was published as a protocol for a trial and in abstract format only, and it is unclear whether the trial was completed (<LINK REF="STD-Kostadinova-2012" TYPE="STUDY">Kostadinova 2012</LINK>).</P>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> presents a flow chart of the search screening process for the present update. We identified 461 studies through the database search strategy and none from searching other sources. After removing duplicates and screening titles and abstracts, we retrieved the full text for five studies. Of these, we included four new studies in the review.</P>
<P>For this update we attempted to contact the authors of two studies: to retrieve essential data for <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK> and to check the status of the trial and request a report if available for <LINK REF="STD-Kostadinova-2012" TYPE="STUDY">Kostadinova 2012</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-07-14 15:56:54 +0100" MODIFIED_BY="Anna Erskine">
<P>We present full details of the studies in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
<SUBSECTION>
<HEADING LEVEL="4">Study participants</HEADING>
<P>All included studies evaluated only adult participants (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>).</P>
<P>Nine studies included only people with upper limb CRPS treated with stellate ganglion blockade (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>), and two studies included only people with lower limb CRPS treated with lumbar sympathetic blockade (<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>). The remaining study included a mix of upper and lower limb CRPS (<LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study designs</HEADING>
<P>Two studies used a cross-over design (<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>), and 10 employed a parallel design (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>). All included studies were small, with total numbers of participants ranging from 7 to 82.</P>
<SUBSECTION>
<HEADING LEVEL="5">LASB versus placebo</HEADING>
<P>Two studies compared LASB versus placebo (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>).</P>
<P>
<LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK> (N = 7) compared stellate ganglion block (n = 4, 15 ml lidocaine 1%) versus lumbar sympathetic block (n = 3, 10 ml bupivacaine 0.125%) with normal saline injection in people with CRPS of the upper or lower extremities based on the IASP diagnostic criteria and investigated the proportion of participants who experienced 50% pain relief. <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK> also measured the duration of pain relief and the mean between-group difference in pain relief on a visual analogue scale (VAS). <LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK> (N = 25) compared stellate ganglion lidocaine block (10 ml lidocaine 1%) plus sham stellate ganglion ultrasound block (n = 9) to a double-sham condition (sham stellate ganglion lidocaine (10 ml saline) and ultrasound blocks). Both groups received rehabilitation treatment. Investigators measured spontaneous pain post-treatment and at one-month follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">LASB versus other interventions</HEADING>
<P>In contrast to the original version of this review, we included studies, totaling nine, that compared LASB to other interventions (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>).</P>
<P>
<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK> compared stellate ganglion lidocaine block (10 ml of 1%) plus sham stellate ganglion ultrasound block (n = 9) to stellate ganglion ultrasound 'block' (consisting of ultrasound delivered non-invasively over the stellate ganglion) plus sham stellate ganglion lidocaine block (10 ml of saline; n = 9). Both groups received rehabilitation treatment. Investigators measured the primary outcome of spontaneous pain post-treatment and at one-month follow-up.</P>
<P>
<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK> (N = 19) compared stellate ganglion block with bupivacaine (15 ml of 0.5%; n = 10) versus intravenous regional blockade (IVRB) with guanethidine (20 mg; n = 9) in patients with reflex sympathetic dystrophy. The primary outcome was the intensity of pain (measured using a 100 mm linear scale) measured post-treatment at 15 minutes, 60 minutes, 24 hours and 48 hours as well as at one and three months.</P>
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK> (N = 9, of whom seven completed the study) compared sympathetic block with botulinum toxin A (75 units) plus bupivacaine (10 ml of 0.5%) versus bupivacaine alone (10 ml of 0.5%) in people with CRPS of the lower extremity. The primary outcome was the duration that pain (measured using a VAS) remained below baseline levels.</P>
<P>
<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK> (N = 40) compared sympathetic block of the lumbar plexus with lidocaine and clonidine versus pulsed radiofrequency treatment of the same structure. Investigators measured pain intensity for up to six months follow-up.</P>
<P>
<LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK> (N = 36) compared a course of five stellate ganglion blocks with lidocaine versus a two-week course of corticosteroids (prednisolone) in patients with CRPS following stroke. They used a self developed four-point scale (0 to 3) of hand pain with passive movement and followed patients up to 30 days from the start of treatment.</P>
<P>
<LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK> (N = 43) compared sympathetic block with lidocaine (70 mg 1% lidocaine) versus sympathetic block with lidocaine (70 mg 1% lidocaine) plus clonidine (30 &#956;g) versus IVRB with lidocaine plus clonidine (7.0 ml solution, 1% lidocaine, 1 &#956;g/kg clonidine). Investigators measured intensity of pain (VAS) and duration of pain relief post-treatment and at one-week follow-up.</P>
<P>
<LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK> (N = 36) compared image-guided thoracic sympathetic block with ropivacaine and triamcinolone versus injection of the same agents into the subcutaneous space. Authors described this comparison condition as an "active control" as it might be predicted to induce physiological effects. This allowed blinding of participants. Investigators followed up participants using the Brief Pain Inventory as an outcome measure at one month and one year. This study did not report a responder analysis.</P>
<P>
<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK> compared continuous stellate ganglion block (SGB; n = 18; 280 ml, 0.125% bupivacaine at 2 ml/h for seven days) versus continuous infraclavicular brachial plexus block (n = 12; 400 ml, 0.125% bupivacaine at 5 ml/h for seven days) in people with CRPS-I of the upper extremity. Both groups received concurrent physiotherapy sessions. The primary outcome was the subscale scores on the neuropathic pain scale measured over a four-week period post-treatment.</P>
<P>
<LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK> (N = 42) compared stellate ganglion block with image guidance to the same block versus no image guidance in participants with CRPS following stroke. Of note, the group with image guidance received a higher dose of lidocaine (10 ml) than the non-guided group (5 ml). Investigators measured pain intensity with a VAS at two- and four-week follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">LASB in addition to other therapies</HEADING>
<P>Two studies evaluated the efficacy of LASB as an addition to other therapeutic management (<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>). <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> evaluated physical therapy and pharmacological treatment with or without SGB (N = 41 per group, 10 cc, equal parts 2% lidocaine and 0.5% bupivacaine) in people with upper limb CRPS with a confirmed sympathetic component to their pain (50% pain reduction with screening, prerandomisation SGB). Investigators measured pain intensity, therapeutic efficacy (proportion with at least 50% pain reduction), and relapse rate at two months post-treatment. <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK> compared SGB (dose not reported) plus rehabilitation versus rehabilitation alone in a group (N = 60) with shoulder-hand syndrome following stroke. Pain (verbal rating scale) was measured at 10 and 20 days post-treatment.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>In total, we excluded 26 studies. For this update, we excluded one study at the full-text stage as it was not an RCT (<LINK REF="STD-Kastler-2013" TYPE="STUDY">Kastler 2013</LINK>). In the last review we excluded two studies (<LINK REF="STD-Rodriguez-2006" TYPE="STUDY">Rodriguez 2006</LINK>; <LINK REF="STD-Rodriguez-2008" TYPE="STUDY">Rodriguez 2008</LINK>), as it was not clear whether they represented original trials in distinct cohorts or an expansion of the included trial by <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>, comprising many of the same participants' data. For this update we have reclassified these two studies to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> and have again attempted to contact the study authors for clarification. See the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details of all studies excluded from all versions of this review.</P>
<P>We also identified one further study awaiting classification (<LINK REF="STD-Kostadinova-2012" TYPE="STUDY">Kostadinova 2012</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-14 16:03:13 +0100" MODIFIED_BY="Anna Erskine">
<P>We present the summary results of the 'Risk of bias' assessment in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. We considered no studies to be at low risk of bias across all domains.</P>
<ALLOCATION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Only two studies clearly described an adequate randomisation process (<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>); we considered the other ten studies to be at unclear risk of bias for this domain. We judged four studies as being at a low risk of bias for allocation concealment (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>), and we assessed six studies as being at unclear risk of bias (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>). The remaining studies used a cross-over study design (risk of bias for allocation concealment not applicable).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-07-14 15:59:39 +0100" MODIFIED_BY="Anna Erskine">
<P>We considered three studies to have blinded participants and personnel adequately (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>) (low risk of performance bias). We considered six studies to be at unclear risk of bias across this domain (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>) as though the interventions were distinguishable, both were active invasive interventions. Three studies were at high risk of bias (<LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>;) as clinicians delivering the interventions were not blinded or the intervention conditions were clearly distinguishable. The outcome of interest for this review was self-reported pain. In this situation, the patient acts as the assessor; therefore risk of detection bias is primarily dependent on participant blinding. For blinding of outcome assessment, we judged five studies to be at low risk of detection bias as they clearly reported blinding of the participants (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>), four studies at unclear risk of bias as it was unclear whether patients were adequately blinded (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>), and three studies were judged to have high risk of detection bias because patients were not adequately blinded (<LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We considered seven studies to be at unclear risk of bias due to incomplete outcome data (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>) as a result of the levels of drop-out reported or incomplete reporting of attrition.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-07-14 15:53:22 +0100" MODIFIED_BY="Anna Erskine">
<P>We judged three studies to be at high risk of bias for this domain due to incomplete reporting of pain scores (<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>). <LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK> carried an unclear risk of bias for incomplete reporting of pain score at a secondary end point.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adequate sample size?</HEADING>
<P>We judged all studies to be at high risk of bias with regard to sample size as all had less than 50 participants per arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adequate duration of follow-up?</HEADING>
<P>We considered all but four studies to be at high or unclear risk of bias based on inadequate duration of follow-up (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>).</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-07-14 16:03:13 +0100" MODIFIED_BY="Anna Erskine">
<P>We judged two studies to be at high risk of bias for other reasons (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>). In <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>, the LASB group had a significantly shorter duration of symptoms at baseline than the IVRB guanethidine group, and participants were significantly older. <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK> had average pain scores at baseline that differed by greater than one point between groups , but authors did not present tests for comparability at baseline. Three studies were at unclear risk of bias (<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>). <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK> and <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> provided no baseline data, and neither <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK> nor <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK> gave details regarding concomitant treatments. We judged the two cross-over studies to be at low risk of bias for carry-over effects (<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>).</P>
<P>There were insufficient data to support a formal statistical analysis of reporting/small study biases for any comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">Sources of funding and conflicts of interest</HEADING>
<P>While not formally included within the 'Risk of bias' assessment, we extracted information regarding study funding and potential conflicts of interest. Seven study reports offered no details regarding these issues (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>; <LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>; <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>).</P>
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK> declared that the authors had filed a patent for the inclusion of botulinum toxin A in sympathetic blocks. <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> declared financial support from governmental and non-profit organisations. No study declared funding from industry sources. <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK> and <LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK> declared no conflict of interest.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-07-14 15:57:52 +0100" MODIFIED_BY="Anna Erskine">
<P>For a summary of all core findings, see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">LASB versus placebo</HEADING>
<P>For the comparison of LASB versus placebo, we rated all evidence as being of moderate quality.</P>
<SUBSECTION>
<HEADING LEVEL="4">Pain intensity</HEADING>
<P>In <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>, there was no difference between lidocaine and normal saline; the same number of participants (6/7) achieved at least 50% pain relief at two weeks. In <LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>, spontaneous pain scores were no different from baseline to post-treatment in either the group receiving lidocaine plus sham ultrasound SGB (Z = &#8722;0.18, P = 0.86) or in the group receiving sham lidocaine plus sham ultrasound (Z = &#8722;0.76, P = 0.45). Authors did not report between-group comparisons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of pain relief</HEADING>
<P>
<LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK> evaluated the duration of pain relief, finding that when local anaesthetic was administered, the mean duration of relief was longer (three days versus 19.9 hours in the saline group). However, short-term relief was similar in both groups. In <LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>, spontaneous pain scores were no different from baseline to one-month follow-up in either the group receiving lidocaine (plus sham ultrasound SGB; Z = &#8722;1.05, P = 0.29) or in the group receiving sham lidocaine and sham ultrasound (Z = &#8722;0.68, P = 0.50). Authors reported no between-group comparisons. None of the included studies reported postintervention analgesic requirements.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse Events</HEADING>
<P>
<LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK> and <LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK> did not report adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LASB versus other interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Pain relief</HEADING>
<P>Most comparative studies reported no significant difference in pain between groups (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>; <LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>; <LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; low to very low quality evidence). <LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK> did not explicitly report between-group differences, although they did not find any within-group differences in spontaneous pain scores between baseline and post-treatment nor at one-month follow-up in either the group receiving lidocaine SGB plus sham ultrasound SGB (Z-scores listed above) or in the group receiving ultrasound SGB plus sham lidocaine (Z = &#8722;0.59, P = 0.55; Z = &#8722;0.63, P = 0.53, respectively; low quality evidence). Due to the variation in the interventions, there were not adequate data to allow pooling of the results.</P>
<P>
<LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK> reported no significant difference in hand pain intensity (scale from 0 to 3) between LASB plus corticosteroid versus oral corticosteroids at 15-day follow-up (mean difference 0.00, 95% confidence interval (CI) &#8722;0.35 to 0.35; very low quality evidence) and a statistically significant difference in favour of LASB with steroid at 30 days (mean difference 0.40, 95% CI &#8722;0.69 to &#8722;0.11; very low quality evidence).</P>
<P>
<LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK> reported that thoracic LASB with ropivacaine and steroid did not result in a statistically significant difference in average pain scores compared to injection of the same agents into the subcutaneous space (described as an "active placebo" at one month (0 to 10 scale mean difference &#8722;1.25, 95% CI &#8722;3.20 to 0.70; very low quality evidence), but there was a statistically significant difference at one-year follow-up in favour of thoracic LASB (mean difference &#8722;2.39, 95% CI &#8722;4.72 to &#8722;0.06; very low quality evidence). While not significant at one-month follow-up, the point estimate at both time points exceeds our threshold for clinical importance. However, it is worth noting that at one-year follow-up, attrition in the active group was 16% and in the control group 26%, introducing a possible risk of bias.</P>
<P>
<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK> reported significantly lower short-term pain scores (on a 0 to 10 scale) in favour of the group receiving the continuous infraclavicular brachial plexus block versus the group receiving the continuous stellate ganglion block. Specifically, at 30 minutes, 2 hours and 12 hours, those receiving the continuous brachial plexus block had significantly lower intensity of pain (0.7, 0.5, and 0.7, respectively) and unpleasantness of pain (0.7, 0.7, and 0.8, respectively) compared with those receiving a continuous stellate ganglion block (intensity: 3.3, 2.7, and 1.9; unpleasantness: 3.0, 2.7, and 1.9). Dull pain intensity scores were significantly reduced for the brachial plexus block group versus the stellate ganglion block group at 2 hours (0.1 versus 2.4), 12 hours (0.6 versus 1.9), and 24 hours (1.3 versus 2.6) with deep pain also significantly reduced at these time points (2 hours &#8722;0.1 versus 2.3; 12 hours &#8722;0.7 versus 1.6; 24 hours &#8722;1.4 versus 2.4), as well as at 30 minutes postcannulation (0.1 versus 2.3). There were no statistically significant differences between groups for short-term scores on any of the other Neuropathic Pain Scale components. Furthermore, there was no evidence of increased effectiveness for long-term pain relief in one group over the other and no between-group differences at any other time points. There was no statistical comparison of quality of pain differences between groups. We rated this evidence as being of low quality.</P>
<P>
<LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK> found no statistically significant or clinically important difference between image-guided and non-guided stellate ganglion block at two weeks postinjection (0 to 10 pain VAS mean difference &#8722;0.58, 95% CI &#8722;1.51 to 0.35; very low quality evidence); there was a statistically significant but clinically unimportant difference at four weeks postinjection (mean difference &#8722;0.74, 95% CI &#8722;1.36 to &#8722;0.12; very low quality evidence) in participants with CRPS following stroke.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of pain relief</HEADING>
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK> reported a significantly longer duration of analgesia in the botulinum toxin A group (median time to analgesic failure 71 days (95% CI 12 to 253; low quality evidence) compared with bupivacaine alone (&lt; 10 days, 95% CI 0 to 12; P &lt; 0.02; low quality evidence). However, while the authors reported that pain intensity declined significantly in the botulinum toxin A group, they did not provide numeric pain scores for either treatment group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Only six studies provided specific data regarding adverse events, and the level of detail of this reporting was mixed.</P>
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK> reported moderate adverse events in one participant (14.2%) following the botulinum toxin type A LASB. This participant had significant nausea and emesis that began five5 hours after the injection and lasted two days, resolving spontaneously.</P>
<P>
<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK> reported that paraesthesia during needle positioning in "1 out of 10" in the LASB group and "2 out of 10" in the pulsed radiofrequency group. This is likely to be an error as it suggests that there were 20 participants in total while the trial reports 40 participants. The study reports that all participants in both groups reported soreness at the injection site lasting five to seven days.</P>
<P>
<LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK> also found mild adverse events for all three groups. The SGB group receiving lidocaine and clonidine (gGroup 2) reported the highest frequency of adverse events: 93.3% reported drowsiness (14/15), 13.3% dizziness (2/15), 13.3% hoarseness (2/15), 6.7% reported pain at the injection site (1/15), and 26.7% reported a feeling of dry mouth (4/15). The SGB group receiving only lidocaine (gGroup 1) reported the lowest frequency of adverse events, with nausea occurring in 6.5% (1/14), dizziness in 14.3% (2/14), hoarseness in 6.5% (1/14), and pain at the injection site in 6.5% (1/14). Lastly, the group receiving the IVintravenous (IV) regional block with lidocaine and clonidine (gGroup 3) reported drowsiness (46.1%; 6/13) and dizziness (7.7%; 1/13).</P>
<P>
<LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK> reported a similar overall rate of minor adverse events following thoracic blockade or subcutaneous injection with local anaesthetic and steroid and no major adverse events. Minor eventsThese included dizziness, blurred vision, puncture pain, increased pain, headache, nausea, vomiting, dysphagia, hoarseness, haematoma, dyspnoea, shivering, cold feeling, face swelling, and mouth numbness. Of note, 65% of participants in both groups reported "puncture pain";, 24% in the thoracic block group reported dyspnoea compared with 6% in the subcutaneous group. 35%Thirty-five per cent in the thoracic block group reported dizziness compared to 12% in the subcutaneous group. Twenty-four per cent in the thoracic block group reported dizziness compared to no participants in the subcutaneous group.</P>
<P>
<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK> found adverse events in both groups. In the continuous stellate ganglion block group, Horner's syndrome was most common (94.7%) while initial motor weakness was the most common adverse event in the continuous infraclavicular brachial plexus group (100%). Positive catheter tip culture occurred in 61.1% (11/18) of the stellate ganglion block group and in 8.3% (1/12) in the brachial plexus group; investigators observed no signs of infection at the catheter site were observed in either group. Catheter migration was found in 5.2% (1/19) of the stellate ganglion block group (versus 7.1% (1/14) of the brachial plexus group). Lastly, hoarseness of voice (for initial 12 hours) was found in 16.7% (3/18) of participants in the stellate ganglion block group reported hoarseness of voice (for initial 12 hours).</P>
<P>
<LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK> reported no adverse events in the group who received ultrasound guided blocks and two haematomas at the injection site for those who received unguided blocks.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LASB in addition to other interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Pain relief</HEADING>
<P>
<LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK> and <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> investigated the effectiveness of adding LASB to rehabilitation versus rehabilitation or medication alone. <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK> found no benefit of adding LASB at 10 days (0-10 Verbal Rating scale mean difference 0.2, 95% CI &#8722;1.3 to 1.7; very low quality evidence) or 20 days (mean difference 0.1, 95% CI &#8722;0.97 to 1.17; very low quality evidence). <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> reported treatment efficacy (proportion with at least 50% pain reduction) at the two-month follow-up to be 46% in favour of the SGB group, an absolute risk reduction of 17% in favour of the SGB group with a number needed to treat for an additional beneficial outcome (NNTB) of 6. The NNTB suggests that six people with CRPS would need to be treated with SGB (in addition to physical and pharmacological therapy) to prevent one relapse. There was a higher relapse rate in the control group (37%) versus the SGB group (20%) (hazard ratio (HR) 2.7, 95% CI 1.1 to 6.7; very low quality evidence). The Kaplan-Meier estimates of the cumulative probability of not having a relapse at two months was 80% in the SGB group and 63% in the control group. However, this study did not report data for pain intensity or the proportion who achieved meaningful pain relief.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of pain relief</HEADING>
<P>No studies specifically presented data on the duration of pain relief for this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>
<LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK> and <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK> did not report adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY_OF_RESULTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>The objective of this review was to assess the efficacy of LASB for the treatment of pain in CRPS and to evaluate the incidence of adverse effects of the procedure.</P>
<P>Previous versions of this review revealed the scarcity of published evidence to support the use of LASB for CRPS and raised questions about its efficacy.</P>
<SUBSECTION>
<HEADING LEVEL="3">LASB versus placebo or no treatment</HEADING>
<P>This update reveals little progress in developing high quality evidence to support the use of LASB for CRPS since the last update in 2013. There are only two placebo-controlled randomised studies that met our modified inclusion criteria for this update (<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>), both of which have very small sample sizes. We can draw no firm conclusions from this evidence. It is notable that the results to date are not suggestive of a significant effect of LASB over placebo even in the very short term (30 minutes to two hours), the time frame that theory would suggest local anaesthetic is likely to have its maximum benefit. We could not estimate the duration of pain relief, if any.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LASB versus other interventions</HEADING>
<P>In a change from the original version of this review, we took the decision to include trials that compared LASB with alternative interventions or that evaluated the effect of adding LASB to other treatments. We identified a number of such studies investigating a range of comparisons, and the majority of these demonstrated no significant difference between the intervention and control groups. It is notable that in one small study (<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>), LASB did not demonstrate superior effectiveness when compared to intravenous regional blockade (IVRB) with guanethidine, an intervention for which there is consistent evidence of no effect (<LINK REF="REF-Jadad-1995" TYPE="REFERENCE">Jadad 1995</LINK>; <LINK REF="REF-McQuay-1997" TYPE="REFERENCE">McQuay 1997</LINK>; <LINK REF="REF-O_x0027_Connell-2013" TYPE="REFERENCE">O'Connell 2013</LINK>).</P>
<P>One small study (N = 36) at high risk of bias suggests a potentially clinically important effect for thoracic sympathetic blockade with bupivacaine and triamcinolone on average daily pain at one month and one year when compared to injection of the same agents into the subcutaneous space, though this difference was not statistically significant at one- month follow-up (<LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>). The subcutaneous injection in this study was used as an active control condition, and might be expected to have systemic effects.</P>
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK> provided limited evidence that, compared with LASB alone, sympathetic blockade with botulinum toxin A added to local anaesthetic may prolong analgesia. Another single study, <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>, provided limited evidence to suggest that when added to usual physical therapy and pharmacological treatment, LASB may reduce the risk of relapse, but we found this study to be at high risk of bias across multiple domains; it did not report data for pain relief, and the lack of a sham condition raises the possibility that the observed improvement may have resulted from non-specific effects. In contrast, <LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK> found no benefit of adding cervical sympathetic blockade to usual comprehensive rehabilitative treatment for pain outcomes.</P>
<P>There is limited evidence that, compared with continuous infraclavicular brachial plexus blocks, continuous stellate ganglion LASB results in less relief in short-term pain intensity, pain unpleasantness, deep pain and dull pain (<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>). The same study also provides limited evidence of no difference in longer-term pain relief (up to four weeks) between groups (<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>).</P>
<P>Given the limited evidence available and the various sources of potential bias and uncertainty, we conclude that there is little credible evidence to support the use of LASB for CRPS and that the majority of the limited evidence available suggests that LASB may be ineffective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>The reporting of adverse events in the identified studies was inconsistent and limited. Given this lack of reporting and the small size of all of the included studies, we cannot confidently draw conclusions regarding the safety of LASB. While those adverse events that have been reported appear to be minor, it is not currently possible to rule out the potential for rare but serious adverse events. To obtain a better estimate of the incidence and nature of adverse events, it might be necessary to review evidence from non-randomised observational study designs, but that was beyond the scope of this review.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>By undertaking a systematic search of unpublished and grey literature and consulting experts in the field, we have limited the risk of excluding important and relevant evidence. We judged all of the included studies as being at unclear risk of bias in at least one domain, reflecting a common lack of clarity in many study reports. We deemed three as being at high risk of bias specifically for the selective reporting of outcomes. This represents a significant challenge to a confident interpretation of an already limited evidence base.</P>
<P>We attempted to contact the authors of seven studies, with mixed success. Two responded and provided available data (<LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>; <LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>). However, as we were unable to source two studies (<LINK REF="STD-Kostadinova-2012" TYPE="STUDY">Kostadinova 2012</LINK>; <LINK REF="STD-Salinas-Cerda-1997" TYPE="STUDY">Salinas Cerda 1997</LINK>), did not receive a response from one to provide full data (<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>), and were unable to include two studies due to lack of clarity over whether the participant population overlapped with another included study (<LINK REF="STD-Rodriguez-2006" TYPE="STUDY">Rodriguez 2006</LINK>; <LINK REF="STD-Rodriguez-2008" TYPE="STUDY">Rodriguez 2008</LINK>), it is possible that we are missing relevant data.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>We did not judge any of the included studies to be at low risk of bias across all domains. Indeed, all but two studies carried an unclear risk of bias for random sequence generation and all but four for allocation concealment. These factors have been demonstrated to exaggerate the effects of studies, particularly those with subjective outcomes, such as pain (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). We assessed all studies to be at high risk of bias for inadequate sample size and only four studies to be at low risk of bias for adequate duration of follow-up. Small studies may well be underpowered to detect a clinical effect, but conversely there is empirical evidence that small published clinical trials in pain have a tendency to exaggerate treatment effects (<LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>; <LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>). These numerous sources of potential bias might alone explain any observed positive effects in the included studies. Thus, all of the evidence identified should be interpreted with caution.</P>
<P>Applying the GRADE approach, ratings across all comparisons were either low or very low quality except for the comparison of LASB versus placebo, which was of moderate quality. This rating is the result of the criteria we decided upon a priori when updating the searches. However, this moderate rating still merits some caution, since it is based on so few data. It is our view that for future updates, the rating of imprecision might be downgraded twice in the event that a comparison consists of fewer than 100 participants. Since each comparison consists of only one or two very small studies, and since all studies are at unclear or high risk of bias across various domains, it would be reasonable to characterise the entire body of included evidence as of low or very low quality.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>While we have attempted to identify all eligible trials using a comprehensive search strategy, we may have still missed some key literature. Only three included studies used a positive response to a prior LASB to attempt to establish sympathetically maintained pain as part of their inclusion criteria (<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>; <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>). This speaks to a wider issue concerning the use of LASB in CRPS. It is possible that LASB might only be effective in a subgroup of people with CRPS with sympathetic dysfunction, or perhaps in people with other characteristics. However, to date evidence of predictors of a positive response to LASB are elusive (<LINK REF="REF-Sethna-2012" TYPE="REFERENCE">Sethna 2012</LINK>).</P>
<P>The decision to exclude studies with only very short term follow-up (&#8804; 48 hours) has led to the exclusion of studies that had been included in previous updates of this review. We took this decision on the basis that such studies are of more value in terms of investigating the diagnostic potential of LASB, which was not the purpose of our review. These studies do not provide clinically useful information in terms of treatment effectiveness over a reasonable period of time. This review focused on pain as a primary outcome and did not consider outcomes such as function or other clinical signs. However, LASB is commonly conducted with the primary goal of pain relief.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Our results do not change the overall conclusions of earlier versions of this review. Similarly a number of earlier systematic reviews have included evaluations of the evidence for LASB, and all have similarly agreed that the evidence is limited and that there is no clear evidence for the efficacy of LASB (<LINK REF="REF-Forouzanfar-2002" TYPE="REFERENCE">Forouzanfar 2002</LINK>; <LINK REF="REF-Perez-2010" TYPE="REFERENCE">Perez 2010</LINK>; <LINK REF="REF-Tran-2010" TYPE="REFERENCE">Tran 2010</LINK>). <LINK REF="REF-Van-Eijs-2011" TYPE="REFERENCE">Van Eijs 2011</LINK> recommended that LASB be considered for the treatment of CRPS if conservative multidisciplinary management has failed. However, they rated the evidence for the effectiveness of CRPS as level 2B+, characterised as "multiple RCTs, with methodologic weaknesses, yield contradictory results better or worse than the control treatment. Benefits closely balanced with risk and burdens, or uncertainty in the estimates of benefits, risk and burdens." This classification of the evidence seems consistent with our own conclusions, though we feel this level of evidence precludes clinical recommendations.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<SUBSECTION>
<HEADING LEVEL="3">For people with CRPS</HEADING>
<P>LASB is a treatment that may be offered for CRPS to help reduce pain and other symptoms. There is a scarcity of published evidence and a lack of high quality evidence to support or refute its effectiveness, though the available evidence is not encouraging. Due to the scarcity of evidence it is not possible to draw confident conclusions about the safety of LASB. People should consider this information when deciding whether to agree to receive the treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">For clinicians</HEADING>
<P>There is a scarcity of published evidence and a lack of high quality evidence to support or refute its effectiveness, though the available evidence is not encouraging. One study, judged to be at high risk of bias, provides very low quality evidence that LASB may reduce the risk of recurrence of pain when added to rehabilitation and standard pharmacological care, and one study, also judged to be at high risk of bias, suggests that thoracic sympathetic block with local anaesthetic and corticosteroid may be effective. However, on the basis of such evidence it is not possible to make any clinical recommendations. Due to the scarcity of evidence it is not possible to draw confident conclusions about the safety of LASB.There is currently little credible evidence to support the use of LASB for CRPS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">For policy makers and funders</HEADING>
<P>The available evidence relating to the effectiveness of LASB for CRPS is not compelling. While there is substantial uncertainty regarding the effectiveness of alternative therapeutic options (<LINK REF="REF-O_x0027_Connell-2013" TYPE="REFERENCE">O'Connell 2013</LINK>), it is not clear that investment in this procedure provides clinical value.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<SUBSECTION>
<HEADING LEVEL="3">General</HEADING>
<P>If LASB is to continue to be offered to people with CRPS, there is a clear need for further, better quality research into its efficacy. It seems likely that the best chance of delivering high quality trials is through multicentre, collaborative research projects that can recruit from larger clinical populations. While many studies investigate the effect of adding therapeutic agents to LASB, there remains substantial uncertainty regarding the efficacy of simple local anaesthetic blockade for CRPS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Design</HEADING>
<P>Reducing this uncertainty requires adequately powered trials that utilise placebo controls, ensure adequate blinding and confirm the technical adequacy of the block. Future trials should use established diagnostic criteria and clearly report the type of CRPS under investigation. Trials should also consider the IMMPACT recommendations for the design of trials in pain to ensure that outcomes, thresholds for clinical importance and study designs are optimal (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>; <LINK REF="REF-Dworkin-2009" TYPE="REFERENCE">Dworkin 2009</LINK>; <LINK REF="REF-Dworkin-2010" TYPE="REFERENCE">Dworkin 2010</LINK>; <LINK REF="REF-Turk-2008a" TYPE="REFERENCE">Turk 2008a</LINK>; <LINK REF="REF-Turk-2008b" TYPE="REFERENCE">Turk 2008b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measurement (endpoints)</HEADING>
<P>Future trials should measure both immediate pain relief and long-term (&#8805; 6 month) outcomes from LASB. Furthermore, future trials should adhere to the CONSORT guidance on standards of reporting and should clearly report all adverse events (<LINK REF="REF-Altman-2012" TYPE="REFERENCE">Altman 2012</LINK>).</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-03-07 16:41:24 +0000" MODIFIED_BY="Anna Erskine">
<P>We thank the Pain, Palliative and Supportive Care Review Group for running the searches and supporting the review process.</P>
<P>We would also like to thank Arturo Lawson, Murat Dalkilinc, Luciana Macedo, Ann Meulders, Eric Parent, Andrea Wand, Eva Bosch and Ein-Soon Shin for their assistance in interpreting non-English language trials.</P>
<P>Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS) or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-07-14 16:07:47 +0100" MODIFIED_BY="Anna Erskine">
<P>NEO: none known.</P>
<P>BMW: none known.</P>
<P>WG: none known.</P>
<P>DBC: none known; DBC practiced anesthesiology and pain medicine in busy academic medical centers from 1986-2005, directly treating patients with CRPS, but has not treated people with CRPS since 2005.</P>
<P>FB: none known; FB is a practicing neurologist and pain treatment specialist who treats patients with CRPS.</P>
<P>TRS: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>NEO: informed the modification of the protocol; acted as the arbiter reviewer; led the data synthesis and the writing of the manuscript.</P>
<P>BMW: informed the modification of the protocol; screened, identified and evaluated studies; extracted data; and contributed to the writing of the manuscript.</P>
<P>WG: informed the modification of the protocol; screened, identified and evaluated studies; extracted data; and contributed to the writing of the manuscript</P>
<P>DBC: designed the original protocol and consulted on the modifications; contributed to the writing of the manuscript.</P>
<P>FB: informed the modification of the protocol; assisted in the clinical trial register searches; and contributed to the writing of the manuscript.</P>
<P>TRS: led the modification and writing of the protocol; performed the literature search; screened, identified and evaluated studies; extracted data; informed the data synthesis; and informed the writing of the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>This 2016 updated review used an expanded search strategy. In particular, we used additional search terms and also searched clinical trial registers for potentially relevant studies. For this update, we excluded studies that had only immediate follow-up data (&#8804; 48 h), because this information provides little clinically relevant information about the clinical effectiveness of this treatment.</P>
<P>Further, we used an updated version of the 'Risk of bias' assessment &#8211; specifically, we included 'size of treatment groups' and 'duration of follow-up' in the 'Risk of bias' evaluation. This updated review also included studies comparing local anaesthetic blockade (LASB) versus other active treatments (original review compared LASB with placebo/inert treatments only). Lastly, we updated the data analysis that included consideration of the minimally important difference (as per OMERACT 12 group recommendations) and evaluation of the level of evidence using the GRADE approach.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-07-28 14:54:36 +0100" MODIFIED_BY="Anna Erskine">
<P>A new search within two years is not likely to identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. The review will be re-assessed for updating in five years. If appropriate, we will update the review before this date if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-07-28 16:15:42 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2016-07-14 16:15:50 +0100" MODIFIED_BY="Anna Erskine">
<INCLUDED_STUDIES MODIFIED="2016-07-14 16:14:45 +0100" MODIFIED_BY="Anna Erskine">
<STUDY DATA_SOURCE="PUB" ID="STD-Aydemir-2006" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Aydemir 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydemir K, Taskaynatan MA, Yazicloglu K, Ozgul A</AU>
<TI>The effects of stellate ganglion block with lidocaine and ultrasound in complex regional pain syndrome: A randomized, double blind, placebo controlled study</TI>
<SO>Journal of Rheumatology and Medical Rehabilitation</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>3</NO>
<PG>193-200</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414464"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414463"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonelli-1983" MODIFIED="2016-06-23 13:59:27 +0100" MODIFIED_BY="[Empty name]" NAME="Bonelli 1983" YEAR="1983">
<REFERENCE MODIFIED="2016-06-23 13:59:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonelli S, Conoscente F, Movilia PG, Restelli L, Francucci B, Grossi E</AU>
<TI>Regional intravenous guanethidine vs. stellate ganglion block in reflex sympathetic dystrophies: a randomized trial</TI>
<SO>Pain</SO>
<YR>1983</YR>
<VL>16</VL>
<NO>3</NO>
<PG>297-307</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroll-2009" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Carroll 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;Author Affiliation: Department of Anesthesiology, Stanford University School of Medicine, Stanford, CA 94304-1573, USA. irc39@pain.stanford.edu&lt;br&gt;Connective Phrase: 19334078&lt;br&gt;Notes: Publication Type: Journal Article. Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 15:46:53 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroll I, Clark JD, Mackey S</AU>
<TI>Sympathetic block with botulinum toxin to treat complex regional pain syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>2009</YR>
<VL>65</VL>
<NO>3</NO>
<PG>348-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414468"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freitas-2013" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Freitas 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;J.W. Chang (Editor), M. Hodaie (Editor), J.K. Krauss (Editor), J. Neimat (Editor), M. Schulder (Editor), T. Taira (Editor), H. Toda (Editor), O. Vilela Filho (Editor); ID: 408&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 15:46:53 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freitas TS, Deusdara R, Kessler I</AU>
<TI>Pulsed radiofrequency of sympathetic lumbar plexus versus sympathetic block in the management of lower limb complex regional pain syndrome type</TI>
<SO>Stereotactic and functional neurosurgery</SO>
<YR>2013</YR>
<VL>91</VL>
<PG>107</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414470"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414469"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2007" MODIFIED="2016-01-04 11:51:26 +0000" MODIFIED_BY="[Empty name]" NAME="Lim 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-01-04 11:51:26 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ID: 11CN-01046041&lt;/p&gt;" NOTES_MODIFIED="2016-01-04 11:51:26 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim K B, Lee H J, Joo S J, Kim J Y, Lim S S</AU>
<TI>The Comparision of Effects between Stellate Ganglion Block and Oral Corticosteroid Therapy in Post-stroke Complex Regional Pain Syndrome</TI>
<SO>Journal of Korean Academy of Rehabilitation Medicine</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>4</NO>
<PG>417-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414472"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nascimento-2010" MODIFIED="2013-07-22 12:15:32 +0100" MODIFIED_BY="[Empty name]" NAME="Nascimento 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-07-22 12:15:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nascimento MSA, Klamt JG, Prado WA</AU>
<TI>Intravenous regional block is similar to sympathetic ganglion block for pain management in patients with complex regional pain syndrome type I</TI>
<SO>Brazilian Journal of Medical and Biological Research</SO>
<YR>2010</YR>
<VL>43</VL>
<NO>12</NO>
<PG>1239-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1998" MODIFIED="2016-06-23 14:03:15 +0100" MODIFIED_BY="[Empty name]" NAME="Price 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-06-23 14:03:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price DD, Long S, Wilsey B, Rafii A</AU>
<TI>Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patients</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>3</NO>
<PG>216-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocha-2014" MODIFIED="2016-07-14 16:14:45 +0100" MODIFIED_BY="Anna Erskine" NAME="Rocha 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-07-14 16:14:45 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;ID: 57CN-01052222&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 16:14:45 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocha RDO, Teixeira MJ, Yeng LT, Cantara MG, Faria VG, Liggieri V et al</AU>
<TI>Thoracic sympathetic block for the treatment of complex regional pain syndrome type I: a double-blind randomized controlled study</TI>
<SO>Pain</SO>
<YR>2014</YR>
<VL>155</VL>
<NO>11</NO>
<PG>2274-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2005" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Rodriguez 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez RF, Bravo LE, Tovar MA, Castro F, Ramos GE, Mendez F</AU>
<TI>Determination of the analgesic efficacy of the stellate ganglion blockade in the alleviation of pain mediated by the sympathetic nervous system in patients with Complex Regional Pain Syndrome</TI>
<TO>Determinacion de la eficacia analgesica de los bloqueos del ganglio estrellado en el alivio del dolor mediado por el sistema nervioso simpatico, en pacientes con sindrome doloroso regional complejo del miembro superior</TO>
<SO>Revista Colombiana de Anestesiología</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>3</NO>
<PG>153-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414480"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toshniwal-2012" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Toshniwal 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toshniwal G, Sunder R, Thomas R, Dureja GP</AU>
<TI>Management of complex regional pain syndrome type I in upper extremity - Evaluation of continuous stellate ganglion block and continuous infraclavicular brachial plexus block: a pilot study</TI>
<SO>Pain Medicine</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>1</NO>
<PG>96-106</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414482"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-12-06 05:55:20 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoo-2012" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Yoo 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;ID: 29CN-01046667&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 15:46:53 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoo SD, Jung SS, Kim HS, Yun DH, Kim DH, Chon J</AU>
<TI>Efficacy of ultrasonography guided stellate ganglion blockade in the stroke patients with complex regional pain syndrome</TI>
<SO>Annals of Rehabilitation Medicine</SO>
<YR>2012</YR>
<VL>36</VL>
<NO>5</NO>
<PG>633-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414484"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2003" MODIFIED="2012-12-06 05:19:12 +0000" MODIFIED_BY="[Empty name]" NAME="Zeng 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-12-06 05:19:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng X, Chen S, Guan C, Jiang L, Wang L</AU>
<TI>Block of ganglion stellatum on improving edema and range of movement in shoulder-hand syndrome</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>7</NO>
<PG>1194-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414486"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414485"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<STUDY DATA_SOURCE="PUB" ID="STD-Ackerman-2006" MODIFIED="2013-07-22 12:21:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ackerman 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-07-22 12:21:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Pain Medicine Consultants PA, Little Rock, AR, USA. William.Ackerman@bhsi.com&lt;br&gt;Connective Phrase: 17100029&lt;br&gt;Author, Monographic: Comment in: South Med J. 2007 Apr; 100(4):411-2; author reply 412; PMID: 17460843&lt;br&gt;Notes: Publication Type: Clinical Trial. Journal Article&lt;/p&gt;" NOTES_MODIFIED="2013-07-22 12:21:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman WE, Zhang JM</AU>
<TI>Efficacy of stellate ganglion blockade for the management of type 1 complex regional pain syndrome</TI>
<SO>Southern Medical Journal</SO>
<YR>2006</YR>
<VL>99</VL>
<NO>10</NO>
<PG>1084-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414488"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414487"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arias-1989" MODIFIED="2013-07-22 12:22:02 +0100" MODIFIED_BY="[Empty name]" NAME="Arias 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-07-22 12:22:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arias LM, Bartkowski R, Grossman KL, Schwartzman RJ, Tom CM</AU>
<TI>Sufentanil stellate ganglion injection in the treatment of refractory reflex sympathetic dystrophy</TI>
<SO>Regional Anesthesia</SO>
<YR>1989</YR>
<VL>14</VL>
<NO>2</NO>
<PG>90-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414490"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414489"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catala-1994" MODIFIED="2008-10-30 18:01:47 +0000" MODIFIED_BY="Jessica Thomas" NAME="Catala 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-10-30 18:01:47 +0000" MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catala E, Ferrandiz M, Aliaga L, Serra R, Castro MA, Villar JM</AU>
<TI>Intravenous lidocaine compared with sympathetic blocks as treatment for post-herpetic neuralgia. A 1-year survey</TI>
<SO>The Pain Clinic</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>3</NO>
<PG>205-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414492"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414491"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellemijn-1994" MODIFIED="2016-06-23 14:04:40 +0100" MODIFIED_BY="[Empty name]" NAME="Dellemijn 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-06-23 14:04:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dellemijn PL, Fields HL, Allen RR, McKay WR, Rowbotham MC</AU>
<TI>The interpretation of pain relief and sensory changes following sympathetic blockade</TI>
<SO>Brain</SO>
<YR>1994</YR>
<VL>117</VL>
<NO>6</NO>
<PG>1475-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414494"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414493"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erickson-1993" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Erickson 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erickson SJ, Hogan QH</AU>
<TI>CT-guided injection of the stellate ganglion: description of technique and efficacy of sympathetic blockade</TI>
<SO>Radiology</SO>
<YR>1993</YR>
<VL>188</VL>
<NO>3</NO>
<PG>707-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414496"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414495"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farcot-1990" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Farcot 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;Author Role: Clinique de la Toussaint, Strasbourg.&lt;br&gt;Connective Phrase: PUBMED 1703428&lt;br&gt;Author, Subsidiary: CN-00072689&lt;br&gt;Notes: ORIGINAL TITLE: Traitements locaux intra-veineux des algodystrophies de la main: buflom&amp;#233;dil versus guan&amp;#233;thidine, suivi &amp;#224; long terme. Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 15:46:53 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farcot JM, Grasser C, Foucher G, Marin Braun F, Ehrler S, Demangeat JL, et al</AU>
<TI>Local intravenous treatment of algodystrophy of the hand: buflomedil versus guanethidine, long term follow-up</TI>
<TO>Traitements locaux intra-veineux des algodystrophies de la main : buflomédil versus guanéthidine, suivi à long terme</TO>
<SO>Annales de Chirurgie de la Main et du Membre Supérieur: Organe Officiel des Sociétés de Chirurgie de la Main</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>4</NO>
<PG>296-304</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414498"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414497"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukusaki-1995" MODIFIED="2008-10-30 18:03:02 +0000" MODIFIED_BY="Jessica Thomas" NAME="Fukusaki 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-10-30 18:03:02 +0000" MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukusaki M, Matsumoto M, Yamaguchi K, Nakamura H, Sumiwaka K</AU>
<TI>The role of nerve blocks to deal with pain associated with cervical radiculopathy</TI>
<SO>The Pain Clinic</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>3</NO>
<PG>219-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414500"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrido-2005" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Garrido 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garrido B, Fernandez-Suarez L, Bosch F, Rabi MC, Hernandez-Arteaga M</AU>
<TI>Complex regional pain syndrome type I. Management with sympathetic blockade and other therapies</TI>
<TO>Síndrome doloroso regional complejo tipo 1.Tratamiento mediante bloqueos simpáticos y más</TO>
<SO>Revista de la Sociedad Española del Dolor</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>7</NO>
<PG>417-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414502"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414501"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glynn-1993" MODIFIED="2008-10-30 18:03:27 +0000" MODIFIED_BY="Jessica Thomas" NAME="Glynn 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-10-30 18:03:27 +0000" MODIFIED_BY="Jessica Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glynn C, Casale R</AU>
<TI>Morphine injected around the stellate ganglion does not modulate the sympathetic nervous system nor does it provide pain relief</TI>
<SO>Pain</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>33</NO>
<PG>37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414506"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414505"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartrick-2004" MODIFIED="2016-06-23 14:06:06 +0100" MODIFIED_BY="[Empty name]" NAME="Hartrick 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-06-23 14:06:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartrick CT, Kovan JP, Naismith P</AU>
<TI>Outcome prediction following sympathetic block for complex regional pain syndrome</TI>
<SO>Pain Practice</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>3</NO>
<PG>222-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414508"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414507"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN71968956" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="ISRCTN71968956" YEAR="2006">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN71968956</AU>
<TI>Percutaneous sympathetic blockade in complex regional pain syndrome type 1: a prospective clinical investigation on predictors of sympatheticaly (sic) maintained pain ID - 7</TI>
<SO>http://www.isrctn.com/ISRCTN71968956</SO>
<YR>(accessed 15 October 2015)</YR>
<PB>Controlled trials register ISRCTN (www.controlled-trials.com/isrctn)</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414504"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414503"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kastler-2013" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Kastler 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kastler A, Aubry S, Sailley N, Michalakis D, Siliman G, Gory G, et al</AU>
<TI>CT-guided stellate ganglion blockade vs. radiofrequency neurolysis in the management of refractory type I complex regional pain syndrome of the upper limb</TI>
<SO>European Radiology</SO>
<YR>2013</YR>
<VL>25</VL>
<NO>5</NO>
<PG>1316-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414510"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414509"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linson-1983" MODIFIED="2016-06-23 14:06:35 +0100" MODIFIED_BY="[Empty name]" NAME="Linson 1983" YEAR="1983">
<REFERENCE MODIFIED="2016-06-23 14:06:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linson MA, Leffert R, Todd DP</AU>
<TI>The treatment of upper extremity reflex sympathetic dystrophy with prolonged continuous stellate ganglion blockade</TI>
<SO>Journal of Hand Surgery</SO>
<YR>1983</YR>
<VL>8</VL>
<NO>2</NO>
<PG>153-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414512"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414511"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmqvist-1992" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Malmqvist 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmqvist ELA, Bengtsson M, Sorensen J</AU>
<TI>Efficacy of stellate ganglion block: a clinical study with bupivacaine</TI>
<SO>Regional Anesthesia</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>6</NO>
<PG>340-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414514"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414513"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier-2009" MODIFIED="2016-01-13 13:24:00 +0000" MODIFIED_BY="[Empty name]" NAME="Meier 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-01-13 13:24:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Anesthesiology, Perioperative and Pain Medicine, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA&lt;br&gt;Connective Phrase: 19602962&lt;br&gt;Notes: Publication Type: Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2016-01-13 13:24:00 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meier PM, Zurakowski D, Berde CB, Sethna NF</AU>
<TI>Lumbar sympathetic blockade in children with complex regional pain syndromes: a double blind placebo-controlled crossover trial</TI>
<SO>Anesthesiology</SO>
<YR>2009</YR>
<VL>111</VL>
<NO>2</NO>
<PG>372-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414516"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414515"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perrigot-1982" MODIFIED="2016-06-23 14:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Perrigot 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-06-23 14:07:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrigot M, Bergego C, Hocini A, Pierrot Deseilligny E</AU>
<TI>Algodystrophic syndrome in hemiplegia. Clinical and therapeutic study</TI>
<TO>Le syndrome algodystrophique chez l'hémiplégique. Etude clinique et thérapeutique</TO>
<SO>Annales de Médecine Interne</SO>
<YR>1982</YR>
<VL>133</VL>
<NO>8</NO>
<PG>544-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414517"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quevedo-2005" MODIFIED="2013-07-22 12:26:34 +0100" MODIFIED_BY="[Empty name]" NAME="Quevedo 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-22 12:26:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Physical Medicine and Rehabilitation, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, JFK Johnson Rehabilitation Institute, Edison, NJ, USA&lt;br&gt;Connective Phrase: 15706564&lt;br&gt;Notes: Publication Type: Case Reports. Journal Article&lt;/p&gt;" NOTES_MODIFIED="2013-07-22 12:26:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quevedo JP, Purgavie K, Platt H, Strax TE</AU>
<TI>Complex regional pain syndrome involving the lower extremity: a report of 2 cases of sphenopalatine block as a treatment option</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2005</YR>
<VL>86</VL>
<NO>2</NO>
<PG>335-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414520"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414519"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raja-1991" MODIFIED="2016-06-23 14:08:24 +0100" MODIFIED_BY="[Empty name]" NAME="Raja 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-06-23 14:08:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Role: Department of Anesthesiology/Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.&lt;br&gt;Connective Phrase: PUBMED 1848966&lt;br&gt;Author, Subsidiary: CN-00074219&lt;br&gt;Notes: Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.&lt;/p&gt;" NOTES_MODIFIED="2016-06-23 14:08:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raja SN, Treede RD, Davis KD, Campbell JN</AU>
<TI>Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain</TI>
<SO>Anesthesiology</SO>
<YR>1991</YR>
<VL>74</VL>
<NO>4</NO>
<PG>691-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414522"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414521"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurmann-2001" MODIFIED="2016-06-23 14:08:48 +0100" MODIFIED_BY="[Empty name]" NAME="Schurmann 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-06-23 14:08:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurmann M, Gradl G, Wizgal I, Tutic M, Moser C, Azad S, et al</AU>
<TI>Clinical and physiologic evaluation of stellate ganglion blockade for complex regional pain syndrome type I</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>1</NO>
<PG>94-100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414526"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414525"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinbrocker-1953" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Steinbrocker 1953" YEAR="1953">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinbrocker O, Neustadt D, Lapin L</AU>
<TI>Shoulder-hand syndrome:sSympathetic block compared with corticotropin and cortisone therapy</TI>
<SO>JAMA</SO>
<YR>1953</YR>
<VL>153</VL>
<NO>9</NO>
<PG>788-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414528"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414527"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-2000" MODIFIED="2016-06-23 14:09:18 +0100" MODIFIED_BY="[Empty name]" NAME="Tran 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-06-23 14:09:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran KM, Frank SM, Raja SN, El Rahmany HK, Kim LJ, Vu B</AU>
<TI>Lumbar sympathetic block for sympathetically maintained pain: changes in cutaneous temperatures and pain perception</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2000</YR>
<VL>90</VL>
<NO>6</NO>
<PG>1396-401</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414530"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414529"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verdugo-1995" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Verdugo 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Verdugo RJ, Moya MF, Cea JG, Salinas HA, Bilbeny CJ</AU>
<TI>Stellate ganglion block in reflex sympathetic dystrophy: a double-blind crossover study</TI>
<SO>Program &amp; Abstracts of the 1st Scientific Meeting of the European Federation of IASP Chapters; 1995 May 18-21; Verona (Italy)</SO>
<YR>1995</YR>
<PG>52</PG>
<PB>European Federation of IASP Chapters (EFIC)</PB>
<CY>Diegum (Belgium)</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414532"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414531"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1985" MODIFIED="2016-06-23 14:10:04 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-06-23 14:10:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang JK, Erickson RP, Ilstrup DM</AU>
<TI>Repeated stellate ganglion blocks for upper-extremity reflex sympathetic dystrophy</TI>
<SO>Regional Anesthesia</SO>
<YR>1985</YR>
<VL>10</VL>
<NO>3</NO>
<PG>125-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414534"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414533"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wehnert-2002" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Wehnert 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;Author Role: Universit&amp;#228;tsklinik des Saarlandes, Orthop&amp;#228;dische Klinik und Poliklinik, Homburg, Germany. ywehnert@yahoo.de&lt;br&gt;Connective Phrase: PUBMED 12436326&lt;br&gt;Author, Subsidiary: CN-00411470&lt;br&gt;Notes: ORIGINAL TITLE: Sympathisch unterhaltener Schmerz (SMP) - Phentolamintest vs. Sympathikusblockade Vergleich zweier diagnostischer Methoden. Publication Type: Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 15:46:53 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wehnert Y, Müller B, Larsen B, Kohn D</AU>
<TI>Sympathetically maintained pain (SMP): phentolamine test vs sympathetic nerve blockade. Comparison of two diagnostic methods</TI>
<TO>Sympathisch unterhaltener Schmerz (SMP) &#8211; Phentolamintest vs. Sympathikusblockade Vergleich zweier diagnostischer Methoden</TO>
<SO>Der Orthopäde</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>11</NO>
<PG>1076-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414536"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414535"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yucel-2009" MODIFIED="2013-01-21 14:20:20 +0000" MODIFIED_BY="[Empty name]" NAME="Yucel 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-21 14:20:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Orthopaedics and Traumatology, University of Duzce, Duzce, Turkey. istemiyucel@yahoo.com&lt;br&gt;Connective Phrase: 19888550&lt;br&gt;Notes: Publication Type: Clinical Trial. Journal Article&lt;/p&gt;" NOTES_MODIFIED="2013-01-21 14:20:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yucel I, Demiraran Y, Ozturan K, Degirmenci E</AU>
<TI>Complex regional pain syndrome type I: efficacy of stellate ganglion blockade</TI>
<SO>Journal of Orthopaedic Traumatology</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>179-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414538"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414537"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-07-14 16:15:50 +0100" MODIFIED_BY="Anna Erskine">
<STUDY DATA_SOURCE="PUB" ID="STD-Kostadinova-2012" MODIFIED="2016-07-14 16:15:50 +0100" MODIFIED_BY="Anna Erskine" NAME="Kostadinova 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-14 16:15:50 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;Using Smart Source Parsing Annual Meeting of the Canadian Anesthesiologists' Society, CAS Quebec City, QC Canada. Conference Start: Conference End: Conference Publication: (var.pagings). 59 2012. Date of Publication: June 2012; ID: 244&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 16:15:50 +0100" NOTES_MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kostadinova M, Blaise G, Homsy A, De Gagne N, Del Pino S F</AU>
<TI>The effect of stellar ganglion block with bupivacaine combined or not with neostigmine on the pain relief in patients with complex regional pain syndrome (1343376)</TI>
<SO>Canadian Journal of Anesthesia. Proceedings of the Canadian Anesthesiologists' Society Annual Meeting; 2012 June 15-18; Quebec City (Canada)</SO>
<YR>2012; Supplement 1</YR>
<PG>1-90</PG>
<PB>Canadian Anesthesiologists' Society</PB>
<CY>Toronto (Canada)</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414540"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414539"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2006" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Rodriguez 2006" YEAR="2006 actually 2004">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez RF, Bravo LE, Tovar MA, Castro F, Ramos GE, Daza P</AU>
<TI>Study of the analgesic efficacy of stellate ganglion blockade in the management of the complex regional pain syndrome in patients with pain mediated by sympathetic nervous system: preliminary study</TI>
<TO>Determinación de la eficacia analgésica de los bloqueosdel ganglio estrellado en el síndrome doloroso regionalcomplejo con dolor mediado por el sistema nerviososimpático: estudio preliminar</TO>
<SO>Revista de la Sociedad Española del Dolor</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>4</NO>
<PG>230-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414542"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414541"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2008" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Rodriguez 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rodriguez RF, Bravo LE, Tovar MA, Ramos GE</AU>
<TI>Sympathetic blockades in sympathetic mediated pain</TI>
<SO>The 12th World Congress of PainAbstract viewer; 2008 Aug 17-22; Glasgow (Scotland)</SO>
<YR>2008</YR>
<PG>PM 349</PG>
<PB>International Association for the Study of Pain (IASP)</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414544"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414543"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salinas-Cerda-1997" MODIFIED="2016-06-06 09:37:22 +0100" MODIFIED_BY="[Empty name]" NAME="Salinas Cerda 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-06-06 09:37:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salinas Cerda, H</AU>
<TI>Reflex sympathetic dystrophy: long-term control of sympatic block with guanethidine</TI>
<TO>Distrofia simpática refleja: control a largo plazo del bloqueo simpático con guanetidina</TO>
<SO>Dolor</SO>
<YR>1997</YR>
<VL>5</VL>
<PG>17-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3414524"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3414523"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-01-05 11:56:16 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-14 16:13:50 +0100" MODIFIED_BY="Anna Erskine">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-14 16:13:50 +0100" MODIFIED_BY="Anna Erskine">
<REFERENCE ID="REF-Albrecht-2006" MODIFIED="2016-07-14 16:13:33 +0100" MODIFIED_BY="Anna Erskine" NAME="Albrecht 2006" TYPE="JOURNAL_ARTICLE">
<AU>Albrecht PJ, Hines S, Eisenberg E, Pud D, Finlay DR, Davar G et al</AU>
<TI>Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome</TI>
<SO>Pain</SO>
<YR>2006</YR>
<VL>120</VL>
<NO>3</NO>
<PG>244-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ali-2000" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ali 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ali Z, Raja SN, Wesselmann U, Fuchs PN, Meyer RA, Campbell JN</AU>
<TI>Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain</TI>
<SO>Pain</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>2</NO>
<PG>161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2012" MODIFIED="2013-07-21 19:29:35 +0100" MODIFIED_BY="Kate Cahill" NAME="Altman 2012" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Moher D, Schultz KF</AU>
<TI>Improving the reporting of randomised trials: The CONSORT statement and beyond</TI>
<SO>Statistics in Medicine</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>25</NO>
<PG>2985-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2016-07-14 16:10:25 +0100" MODIFIED_BY="Anna Erskine" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Binder-2009" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Binder 2009" TYPE="BOOK_SECTION">
<AU>Binder A, Baron R</AU>
<TI>Complex regional pain syndrome, including applications of neural blockade</TI>
<SO>Cousins &amp; Bridenbaugh's Neural Blockade in Clinical Anesthesia and Management of Pain</SO>
<YR>2009</YR>
<PG>1154-68</PG>
<EN>4th</EN>
<ED>Cousins MJ, Carr DB, Horlocker TT, Bridenbaugh PO</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birklein-2000" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Birklein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Birklein F, Weber M, Neundörfer B</AU>
<TI>Increased skin lactate in complex regional pain syndrome: evidence for tissue hypoxia?</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>8</NO>
<PG>1213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birklein-2001" MODIFIED="2016-06-23 14:12:29 +0100" MODIFIED_BY="[Empty name]" NAME="Birklein 2001" TYPE="JOURNAL_ARTICLE">
<AU>Birklein F, Schmelz M, Schifter S, Weber M</AU>
<TI>The important role of neuropeptides in complex regional pain syndrome</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>12</NO>
<PG>2179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birklein-2014" MODIFIED="2016-07-14 16:13:46 +0100" MODIFIED_BY="Anna Erskine" NAME="Birklein 2014" TYPE="JOURNAL_ARTICLE">
<AU>Birklein F, Drummond PD, Li W, Schlereth T, Albrecht N, Finch PM et al</AU>
<TI>Activation of cutaneous immune responses in complex regional pain syndrome</TI>
<SO>Journal of Pain</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>5</NO>
<PG>485-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breivik-2009" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Breivik 2009" TYPE="BOOK_SECTION">
<AU>Breivik H, Cousins MJ</AU>
<TI>Sympathetic neural blockade of upper and lower extremity</TI>
<SO>Cousins &amp; Bridenbaugh's Neural Blockade in Clinical Anesthesia and Management of Pain</SO>
<YR>2009</YR>
<PG>848-85</PG>
<EN>4th</EN>
<ED>Cousins MJ, Carr DB, Horlocker TT, Bridenbaugh PO</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruehl-1999" MODIFIED="2016-07-14 16:13:50 +0100" MODIFIED_BY="Anna Erskine" NAME="Bruehl 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bruehl S, Harden RN, Galer BS, Saltz S, Bertram M, Backonja M et al</AU>
<TI>External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria</TI>
<SO>Pain</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>1-2</NO>
<PG>147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruehl-2010" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Bruehl 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bruehl S</AU>
<TI>An update on the pathophysiology of complex regional pain syndrome</TI>
<SO>Anesthesiology</SO>
<YR>2010</YR>
<VL>113</VL>
<NO>3</NO>
<PG>713-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Busse-2015" MODIFIED="2016-07-14 16:10:50 +0100" MODIFIED_BY="Anna Erskine" NAME="Busse 2015" TYPE="JOURNAL_ARTICLE">
<AU>Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR et al</AU>
<TI>Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 workshop</TI>
<SO>Journal of Rheumatology</SO>
<YR>2015</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1962-1970</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-1996" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Campbell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Campbell JN</AU>
<TI>Complex regional pain syndrome and the sympathetic nervous system</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>68</VL>
<PG>89-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carr-2011" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Carr 2011" TYPE="JOURNAL_ARTICLE">
<AU>Carr DB</AU>
<TI>Local anesthetic blockade for neuralgias: &#8220;Why is the sky blue, daddy?&#8221;</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2011</YR>
<VL>112</VL>
<NO>6</NO>
<PG>1285</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Mos-2007" MODIFIED="2013-07-22 12:38:41 +0100" MODIFIED_BY="[Empty name]" NAME="De Mos 2007" TYPE="JOURNAL_ARTICLE">
<AU>De Mos M, De Bruijn AGJ, Huygen FJPM, Dieleman JP, Stricker BHC, Sturkenboom MCJM</AU>
<TI>The incidence of complex regional pain syndrome: a population-based study</TI>
<SO>Pain</SO>
<YR>2007</YR>
<VL>129</VL>
<NO>1-2</NO>
<PG>12-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Mos-2008" MODIFIED="2013-07-22 12:39:10 +0100" MODIFIED_BY="[Empty name]" NAME="De Mos 2008" TYPE="JOURNAL_ARTICLE">
<AU>De Mos M, Huygen FJPM, Dieleman JP, Koopman JSHA, Stricker BHC, Sturkenboom MCJM</AU>
<TI>Medical history and the onset of complex regional pain syndrome (CRPS)</TI>
<SO>Pain</SO>
<YR>2008</YR>
<VL>139</VL>
<NO>2</NO>
<PG>458-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Mos-2009" MODIFIED="2013-07-22 12:39:33 +0100" MODIFIED_BY="[Empty name]" NAME="De Mos 2009" TYPE="JOURNAL_ARTICLE">
<AU>De Mos, Sturkenboom MCJM, Huygen FJPM</AU>
<TI>Current understandings on complex regional pain syndrome</TI>
<SO>Pain Practice</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>2</NO>
<PG>86-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drummond-2001" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Drummond 2001" TYPE="JOURNAL_ARTICLE">
<AU>Drummond PD, Finch PM, Skipworth S, Blockey P</AU>
<TI>Pain increases during sympathetic arousal in patients with complex regional pain syndrome</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>7</NO>
<PG>1296-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drummond-2004" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Drummond 2004" TYPE="JOURNAL_ARTICLE">
<AU>Drummond PD, Finch PM</AU>
<TI>Persistence of pain induced by startle and forehead cooling after sympathetic blockade in patients with complex regional pain syndrome</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>1</NO>
<PG>98-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2016-07-14 16:11:07 +0100" MODIFIED_BY="Anna Erskine" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>2</NO>
<PG>105-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2009" MODIFIED="2016-07-14 16:11:12 +0100" MODIFIED_BY="Anna Erskine" NAME="Dworkin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P et al</AU>
<TI>Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Pain</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>3</NO>
<PG>238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2010" MODIFIED="2016-07-14 16:11:15 +0100" MODIFIED_BY="Anna Erskine" NAME="Dworkin 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB et al</AU>
<TI>Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>149</VL>
<NO>2</NO>
<PG>177-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fine-1994" MODIFIED="2016-06-23 14:15:34 +0100" MODIFIED_BY="[Empty name]" NAME="Fine 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fine PG, Roberts WJ, Gillette RG, Child TR</AU>
<TI>Slowly developing placebo responses confound tests of intravenous phentolamine to determine mechanisms underlying idiopathic chronic low back pain</TI>
<SO>Pain</SO>
<YR>1994</YR>
<VL>56</VL>
<NO>2</NO>
<PG>235-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forouzanfar-2002" MODIFIED="2013-07-22 12:43:37 +0100" MODIFIED_BY="[Empty name]" NAME="Forouzanfar 2002" TYPE="OTHER">
<AU>Forouzanfar T, Koke AJ, Van Kleef M, Weber WE</AU>
<TI>Treatment of complex regional pain syndrome type I</TI>
<SO>European Journal of Pain</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>2</NO>
<PG>105-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geha-2008" MODIFIED="2013-07-22 12:44:15 +0100" MODIFIED_BY="[Empty name]" NAME="Geha 2008" TYPE="JOURNAL_ARTICLE">
<AU>Geha PY, Baliki MN, Harden RN, Bauer WR, Parrish TB, Apkarian AV</AU>
<TI>The brain in chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic regions</TI>
<SO>Neuron</SO>
<YR>2008</YR>
<VL>60</VL>
<NO>4</NO>
<PG>570-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2016-07-14 16:11:25 +0100" MODIFIED_BY="Anna Erskine" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2016-07-14 16:11:27 +0100" MODIFIED_BY="Anna Erskine" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings table</TI>
<SO>Clinical Journal of Clinical Epidemiology</SO>
<YR>2011a</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harden-2006" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Harden 2006" TYPE="BOOK_SECTION">
<AU>Harden RN, Bruehl S</AU>
<TI>Introduction and diagnostic considerations</TI>
<SO>Complex Regional Pain Syndrome: Treatment Guidelines</SO>
<YR>2006</YR>
<ED>Harden RN</ED>
<PB>Reflex Sympathetic Dystrophy Syndrome Association</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harden-2010" MODIFIED="2016-07-14 16:11:35 +0100" MODIFIED_BY="Anna Erskine" NAME="Harden 2010" TYPE="JOURNAL_ARTICLE">
<AU>Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C et al</AU>
<TI>Validation of proposed diagnostic criteria for complex regional pain syndrome</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>150</VL>
<NO>2</NO>
<PG>268-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harden-2013" MODIFIED="2016-07-14 16:11:42 +0100" MODIFIED_BY="Anna Erskine" NAME="Harden 2013" TYPE="JOURNAL_ARTICLE">
<AU>Harden RN, Oaklander AL, Burton AW, Perez RS, Richardson K, Swan M et al</AU>
<TI>Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition</TI>
<SO>Pain Medicine</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>2</NO>
<PG>180-229</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-06-23 14:17:56 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-07-22 12:45:33 +0100" MODIFIED_BY="Kate Cahill" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from: www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogan-1997" MODIFIED="2016-06-23 14:18:21 +0100" MODIFIED_BY="[Empty name]" NAME="Hogan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hogan QH, Abram SE</AU>
<TI>Neural blockade for diagnosis and prognosis. A review</TI>
<SO>Anesthesiology</SO>
<YR>1997</YR>
<VL>86</VL>
<NO>1</NO>
<PG>216-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1995" MODIFIED="2016-06-23 14:18:44 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1995" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Carroll D, Glynn CJ, McQuay HJ</AU>
<TI>Intravenous regional sympathetic blockade for pain relief in reflex sympathetic dystrophy: a systematic review and a randomized, double blind crossover study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>1</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00e4_nig-2003" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Jänig 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jänig W, Baron R</AU>
<TI>Complex regional pain syndrome: mystery explained?</TI>
<SO>The Lancet Neurology</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>11</NO>
<PG>687-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koban-2003" MODIFIED="2016-06-23 14:19:06 +0100" MODIFIED_BY="[Empty name]" NAME="Koban 2003" TYPE="JOURNAL_ARTICLE">
<AU>Koban M, Leis S, Schultze-Mosgau S, Birklein F</AU>
<TI>Tissue hypoxia in complex regional pain syndrome</TI>
<SO>Plastic and Reconstructive Surgery</SO>
<YR>2003</YR>
<VL>104</VL>
<NO>1-2</NO>
<PG>149-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-2007" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Lewis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lewis JS, Kersten P, Mccabe CS, Mcpherson KM, Blake DR</AU>
<TI>Body perception disturbance: a contribution to pain in complex regional pain syndrome (CRPS)</TI>
<SO>Pain</SO>
<YR>2007</YR>
<VL>133</VL>
<NO>1-3</NO>
<PG>111-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lotze-2007" MODIFIED="2013-07-22 12:47:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lotze 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lotze M, Moseley GL</AU>
<TI>Role of distorted body image in pain</TI>
<SO>Current Rheumatology Reports</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>6</NO>
<PG>488-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maih_x00f6_fner-2004" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Maihöfner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Maihöfner C, Handwerker HO, Neundörfer B, Birklein F</AU>
<TI>Cortical reorganization during recovery from complex regional pain syndrome</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>4</NO>
<PG>693-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marinus-2011" MODIFIED="2016-07-14 16:11:59 +0100" MODIFIED_BY="Anna Erskine" NAME="Marinus 2011" TYPE="JOURNAL_ARTICLE">
<AU>Marinus J, Moseley GL, Birklein F, Baron R, Maihofner C, Kingery WS et al</AU>
<TI>Clinical features and pathophysiology of complex regional pain syndrome</TI>
<SO>The Lancet Neurology</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>7</NO>
<PG>637-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1997" MODIFIED="2013-07-22 12:49:41 +0100" MODIFIED_BY="[Empty name]" NAME="McQuay 1997" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ, Moore RA, Eccleston C, Morley S, Williams AC</AU>
<TI>Systematic review of outpatient services for chronic pain control</TI>
<SO>Health Technology Assessment</SO>
<YR>1997</YR>
<VL>1</VL>
<NO>6</NO>
<PG>1-135</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merskey-1994" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Merskey 1994" TYPE="BOOK">
<AU>Merskey H, Bogduk N</AU>
<SO>Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms</SO>
<YR>1994</YR>
<EN>2nd</EN>
<PB>IASP Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2008" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Moore 2008" TYPE="BOOK_SECTION">
<AU>Moore RA, Barden J, Derry S, McQuay HJ</AU>
<TI>Managing potential publication bias</TI>
<SO>Systematic Reviews in Pain research: Methodology Refined</SO>
<YR>2008</YR>
<PG>15-23</PG>
<ED>McQuay HJ, Kalso E, Moore RA</ED>
<PB>IASP Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010" MODIFIED="2016-07-14 16:12:07 +0100" MODIFIED_BY="Anna Erskine" NAME="Moore 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S et al</AU>
<TI>"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>150</VL>
<NO>3</NO>
<PG>386-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moseley-2006" MODIFIED="2016-07-14 16:12:11 +0100" MODIFIED_BY="Anna Erskine" NAME="Moseley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moseley GL</AU>
<TI>Why do people with complex regional pain syndrome take longer to recognize their affected hand?</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>62</VL>
<NO>12</NO>
<PG>2182-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Nelson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nelson DV, Stacey BR</AU>
<TI>Interventional therapies in the management of complex regional pain syndrome</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>5</NO>
<PG>438-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Niehof-2006" MODIFIED="2013-07-22 12:51:21 +0100" MODIFIED_BY="[Empty name]" NAME="Niehof 2006" TYPE="JOURNAL_ARTICLE">
<AU>Niehof SP, Huygen FJPM, Van der Weerd RWP, Westra M, Zijlstra FJ</AU>
<TI>Thermography imaging during static and controlled thermoregulation in complex regional pain syndrome type 1: diagnostic value and involvement of the central sympathetic system</TI>
<SO>BioMedical Engineering Online</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2010" MODIFIED="2016-07-14 16:12:21 +0100" MODIFIED_BY="Anna Erskine" NAME="Nüesch 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AWS, Tschannen B, Altman DG et al</AU>
<TI>Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<NO>7766</NO>
<PG>241</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connell-2013" MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine" NAME="O'Connell 2013" TYPE="COCHRANE_REVIEW">
<AU>O'Connell NE, Wand BM, McAuley J, Marston L, Moseley GL</AU>
<TI>Interventions for treating pain and disability in adults with complex regional pain syndrome- an overview of systematic reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-02-12 14:25:49 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-12 14:25:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009416.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ochoa-1995" MODIFIED="2016-06-23 14:20:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ochoa 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ochoa JL, Verdugo RJ</AU>
<TI>Reflex sympathetic dystrophy. A common clinical avenue for somatoform expression</TI>
<SO>Neurologic Clinics</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>2</NO>
<PG>351-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez-2010" MODIFIED="2016-07-14 16:12:30 +0100" MODIFIED_BY="Anna Erskine" NAME="Perez 2010" TYPE="JOURNAL_ARTICLE">
<AU>Perez RS, Zollinger PE, Dijkstra PU, Thomassen-Hilgersom IL, Zuurmond WW, Rosenbrand KCJ et al</AU>
<TI>Evidence-based guidelines for complex regional pain syndrome type 1</TI>
<SO>BMC Neurology</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pleger-2006" MODIFIED="2016-07-14 16:12:33 +0100" MODIFIED_BY="Anna Erskine" NAME="Pleger 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pleger B, Ragert P, Schwenkreis P, Forster AF, Wilimzig C, Dinse H et al</AU>
<TI>Patterns of cortical reorganization parallel impaired tactile discrimination and pain intensity in complex regional pain syndrome</TI>
<SO>Neuroimage</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>2</NO>
<PG>503-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reinders-2002" MODIFIED="2016-07-14 16:12:38 +0100" MODIFIED_BY="Anna Erskine" NAME="Reinders 2002" TYPE="JOURNAL_ARTICLE">
<AU>Reinders MF, Geertzen JHB, Dijkstra PU</AU>
<TI>Complex Regional Pain Syndrome: Use of the International Association for the Study of Pain Diagnostic Criteria Defined in 1994</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>4</NO>
<PG>207-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-07-11 12:00:38 +0100" MODIFIED_BY="Anna Hobson" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandroni-2003" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Sandroni 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sandroni P, Benrud-Larson LM, McClelland RL, Low PA</AU>
<TI>Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study</TI>
<SO>Pain</SO>
<YR>2003</YR>
<VL>103</VL>
<NO>1-2</NO>
<PG>199-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schinkel-2006" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Schinkel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M</AU>
<TI>Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>3</NO>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmelz-2001" MODIFIED="2016-06-23 14:21:06 +0100" MODIFIED_BY="[Empty name]" NAME="Schmelz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Schmelz M, Weber M, Birklein F, Neundo B</AU>
<TI>Facilitated neurogenic inflammation in complex regional pain syndrome</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>3</NO>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schott-1995" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Schott 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schott GD</AU>
<TI>An unsympathetic view of pain</TI>
<SO>The Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<NO>8950</NO>
<PG>634-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2016-06-23 14:22:27 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwenkreis-2003" MODIFIED="2016-06-23 14:22:49 +0100" MODIFIED_BY="[Empty name]" NAME="Schwenkreis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Schwenkreis P, Janssen F, Rommel O, Pleger B, Volker B, Hosbach I, et al</AU>
<TI>Bilateral motor cortex disinhibition in complex regional pain syndrome (CRPS) type I of the hand</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>4</NO>
<PG>515-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sethna-2012" MODIFIED="2013-07-31 13:05:03 +0100" MODIFIED_BY="[Empty name]" NAME="Sethna 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sethna NF</AU>
<TI>Sympathetic nerve blocks, pragmatic trials and responder analysis</TI>
<SO>Anesthesiology</SO>
<YR>2012</YR>
<VL>116</VL>
<NO>1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shipton-2009" MODIFIED="2016-06-23 14:35:35 +0100" MODIFIED_BY="[Empty name]" NAME="Shipton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Shipton EA</AU>
<TI>Complex regional pain syndrome: mechanisms, diagnosis, and management</TI>
<SO>Current Anaesthesia and Critical Care</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>5-6</NO>
<PG>209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanton_x002d_Hicks-1995" MODIFIED="2008-10-30 18:05:43 +0000" MODIFIED_BY="Jessica Thomas" NAME="Stanton-Hicks 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stanton-Hicks 1995</AU>
<TI>Reflex sympathetic dystrophy: changing concepts and taxonomy</TI>
<SO>Pain</SO>
<YR>1995</YR>
<VL>63</VL>
<NO>1</NO>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanton_x002d_Hicks-2002" MODIFIED="2016-07-14 16:12:58 +0100" MODIFIED_BY="Anna Erskine" NAME="Stanton-Hicks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stanton-Hicks MD, Burton AW, Bruehl SP, Carr DB, Harden RN, Hassenbusch SJ et al</AU>
<TI>An updated interdisciplinary clinical pathway for CRPS: report of an expert panel</TI>
<SO>Pain Practice</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>1-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swart-2009" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Swart 2009" TYPE="JOURNAL_ARTICLE">
<AU>Swart CMA, Stins JF, Beek PJ</AU>
<TI>Cortical changes in complex regional pain syndrome (CRPS)</TI>
<SO>European Journal of Pain</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>9</NO>
<PG>902-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2005" MODIFIED="2011-09-22 08:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Tan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tan ECTH, Oyen WJG, Goris RJA</AU>
<TI>Leukocytes in complex regional pain syndrome type I</TI>
<SO>Inflammation</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>4-6</NO>
<PG>182-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tran-2010" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Tran 2010" TYPE="OTHER">
<AU>Tran DQH, Duong S, Bertini P, Finlayson R</AU>
<TI>Treatment of complex regional pain syndrome: a review of the evidence</TI>
<SO>Canadian Journal of Anesthesia</SO>
<YR>2010</YR>
<VL>57</VL>
<NO>2</NO>
<PG>149-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turk-2008a" MODIFIED="2016-07-14 16:13:06 +0100" MODIFIED_BY="Anna Erskine" NAME="Turk 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D et al</AU>
<TI>Identifying important outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain</TI>
<SO>Pain</SO>
<YR>2008</YR>
<VL>137</VL>
<NO>2</NO>
<PG>276-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turk-2008b" MODIFIED="2016-07-14 16:13:11 +0100" MODIFIED_BY="Anna Erskine" NAME="Turk 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM et al</AU>
<TI>Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations</TI>
<SO>Pain</SO>
<YR>2008</YR>
<VL>139</VL>
<NO>3</NO>
<PG>485-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Eijs-2011" MODIFIED="2016-07-14 16:13:14 +0100" MODIFIED_BY="Anna Erskine" NAME="Van Eijs 2011" TYPE="JOURNAL_ARTICLE">
<AU>Van Eijs F, Stanton-Hicks M, Van Zundert J, Faber CG, Lubenow TR, Mekhail N et al</AU>
<TI>Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome</TI>
<SO>Pain Practice</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>5</NO>
<PG>70-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Rijn-2011" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Van Rijn 2011" TYPE="JOURNAL_ARTICLE">
<AU>Van Rihn MA, Marinus J, Putter H, Bosselaar SRJ, Moseley GL, Van Hilten JJ</AU>
<TI>Spreading of complex regional pain syndrome: not a random process</TI>
<SO>Journal of Neural Transmission</SO>
<YR>2011</YR>
<VL>118</VL>
<NO>9</NO>
<PG>1301-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verdugo-1994a" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NAME="Verdugo 1994a" TYPE="JOURNAL_ARTICLE">
<AU>Verdugo RJ, Ochoa JL</AU>
<TI>Sympathetically maintained pain I. Phentolamine block questions the concept</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>6</NO>
<PG>1003-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verdugo-1994b" MODIFIED="2016-06-23 14:39:27 +0100" MODIFIED_BY="[Empty name]" NAME="Verdugo 1994b" TYPE="JOURNAL_ARTICLE">
<AU>Verdugo RJ, Campero M, Ochoa JL</AU>
<TI>Phentolamine sympathetic block in painful polyneuropathies. II. Further questioning of the concept of "sympathetically maintained pain"</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>6</NO>
<PG>1010-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2016-07-14 16:13:22 +0100" MODIFIED_BY="Anna Erskine" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<REFERENCE ID="REF-Cepeda-2002" MODIFIED="2013-07-30 07:27:16 +0100" MODIFIED_BY="[Empty name]" NAME="Cepeda 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cepeda MS, Lau J, Carr DB</AU>
<TI>Defining the therapeutic role of local anesthetic sympathetic blockade in complex regional pain syndrome: a narrative and systematic review</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>4</NO>
<PG>216-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cepeda-2005" MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" NAME="Cepeda 2005" TYPE="COCHRANE_REVIEW">
<AU>Cepeda S, Carr D</AU>
<TI>Local anesthetic sympathetic blockade for complex regional pain syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-07-23 11:16:27 +0100" MODIFIED_BY="Anna Hobson"><IDENTIFIER MODIFIED="2013-07-23 11:14:23 +0100" MODIFIED_BY="Anna Hobson" TYPE="DOI" VALUE="10.1002/14651858.CD004598"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cepeda-2010" MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" NAME="Cepeda 2010" TYPE="COCHRANE_REVIEW">
<AU>Cepeda MS, Carr DB, Lau J</AU>
<TI>Local anaesthetic sympathetic blockade for complex regional pain syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-07-23 11:16:13 +0100" MODIFIED_BY="Anna Hobson"><IDENTIFIER MODIFIED="2013-07-23 11:16:13 +0100" MODIFIED_BY="Anna Hobson" TYPE="DOI" VALUE="10.1002/14651858.CD004598.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stanton-2013" MODIFIED="2016-07-14 15:48:11 +0100" MODIFIED_BY="Anna Erskine" NAME="Stanton 2013" TYPE="COCHRANE_REVIEW">
<AU>Stanton TR, Wand BM, Carr DB, Birklein F, Wasner GL, O'Connell NE</AU>
<TI>Local anaesthetic sympathetic blockade for complex regional pain syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2016-07-14 15:48:11 +0100" MODIFIED_BY="Anna Erskine"><IDENTIFIER MODIFIED="2016-07-14 15:48:11 +0100" MODIFIED_BY="Anna Erskine" TYPE="DOI" VALUE="10.1002/14651858.CD004598.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Country of origin" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Study aim" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Aydemir-2006">
<CHAR_METHODS MODIFIED="2012-12-05 06:32:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, parallel design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 25; divided into 3 groups (group 1: n = 9; group 2: n = 9; group 3: n = 7)</P>
<P>Mean age (SD):</P>
<P>Group 1: 21.9 years (1.05)</P>
<P>Group 2: 21.4 years (0.73)</P>
<P>Group 3: 21.1 years (0.38)</P>
<P>Sex: not reported.</P>
<P>Upper limb CRPS-I (dominant arm: group 1, n = 6; group 2, n = 9; group 3, n = 2); excluded if had SGB block in last month.</P>
<P>Diagnostic criteria: IASP (<LINK REF="REF-Bruehl-1999" TYPE="REFERENCE">Bruehl 1999</LINK>)</P>
<P>Duration of symptoms:</P>
<P>Group 1 (0-3 months, n = 5; 3-6 months, n = 2; &gt; 6 months, n = 2)</P>
<P>Group 2 (0-3 months, n = 6; 3-6 months, n = 2; &gt; 6 months, n = 1)</P>
<P>Group 3 (0-3 months, n = 5; 3-6 months, n = 0; &gt; 6 months, n = 2)</P>
<P>Type of initiating injury:</P>
<P>Group 1 (trauma, n = 7; fracture, n = 2; idiopathic, n = 0)</P>
<P>Group 2 (trauma, n = 2; fracture, n = 5; idiopathic, n = 2)</P>
<P>Group 3 (trauma, n = 3; fracture, n = 4; idiopathic, n = 0)</P>
<P>Concomitant treatments: all groups received 21 sessions of physiotherapy, which involved exercises, contrast baths, transcutaneous electrical nerve stimulation (TENS), and pneumatic compression. If necessary, all groups had access to medical treatment, which involved 500 mg oral paracetamol pill, maximum of six tablets (3 g) per day.</P>
<P>Medicolegal factors: not reported</P>
<P>Previous treatment: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Group 1: stellate ganglion lidocaine block (real) plus sham stellate ganglion ultrasound block</P>
<P>Group 2: stellate ganglion ultrasound block (real) plus sham stellate ganglion lidocaine block</P>
<P>Group 3: sham stellate ganglion lidocaine block and sham stellate ganglion ultrasound block</P>
<P>For the purpose of this review, we included comparisons between group 1 and group 3 as placebo-controlled and comparisons of group 1 and group 2 as comparison with another active intervention.</P>
<P>SGB lidocaine (real):</P>
<P>Location: C6 level; 1.5 cm lateral to central line, 4-5 cm deep</P>
<P>Dosage: 10 ml of 1% lidocaine</P>
<P>Number of blocks performed: 10</P>
<P>Eval. of technical adequacy of block: No.</P>
<P>SGB (sham):</P>
<P>Identical site, but injected 10 ml of saline.</P>
<P>Number of blocks not reported.</P>
<P>SGB ultrasound (real):</P>
<P>Probe size of 1 cm<SUP>2</SUP>; 5 min of intermittent ultrasound at 3 watt/cm<SUP>2</SUP> over the affected site (over stellate ganglion)</P>
<P>Number of treatments not reported</P>
<P>SGB ultrasound (sham):</P>
<P>5 min, no energy delivered</P>
<P>Number of treatments not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Spontaneous pain:</P>
<P>0-10cm visual analogue scale</P>
<P>Outcomes measured pretreatment, post-treatment, and at one-month follow-up</P>
<P>Adverse events/side effects not reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-12-05 06:52:31 +0000" MODIFIED_BY="[Empty name]">
<P>Turkey</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-12-05 06:54:28 +0000" MODIFIED_BY="[Empty name]">
<P>To investigate the efficacies of stellate ganglion blockage (SGB) with lidocaine and ultrasound in CRPS</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>This study was translated and interpreted by a researcher fluent in Turkish. The study author, TS, worked with the researcher to fully interpret and score.</P>
<P>Conflict of interests not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Bonelli-1983">
<CHAR_METHODS MODIFIED="2012-09-25 14:18:02 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 19</P>
<P>Mean age (SD): 52.33 years (5.04)</P>
<P>Sex: not reported</P>
<P>Diagnosis of RSD following peripheral nerve injury</P>
<P>At least 3 of the following clinical signs: hyperpathia, allodynia, vasomotor disturbance, trophic signs, oedema, limited motion</P>
<P>Mean (SD) duration of pain:</P>
<P>Stellate ganglion block group: 6.55 (3.94) months</P>
<P>IVRB guanethidine group: 17.55(14.9) months</P>
<P>Previous treatment not reported; concomitant treatment not reported</P>
<P>2 lost to follow-up at 3 months in SGB group</P>
<P>Baseline pain (0-100 scale) mean (SD):</P>
<P>Stellate ganglion block group: 70.5 (27.36)</P>
<P>IVRB guanethidine group: 65 (25.46)</P>
<P>Medico-legal factors: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>SGB (n = 10) versus IVRB guanethidine block (n = 9); treatment period of 16 days</P>
<P>SGB: bupivacaine (0.5%) 15 ml</P>
<P>No. of blocks: 8 (1 every other day for 16 days)</P>
<P>Evaluation of adequacy of block? Skin temperature, plethysmographic wave</P>
<P>IVRB guanethidine (20 ml), heparin (500 &#956;l), isotonic saline (25 ml)</P>
<P>No. of blocks: 4 (every 4 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain: 100 mm linear scale (specific details not reported)</P>
<P>Pain measured at baseline and post-treatment at 15 min, 60 min, 24 h, 48 h, 1 month and 3 months</P>
<P>Adverse events only mentioned in discussion (alludes to none in either group)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-09-25 14:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>Italy</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To compare the effects of regional IVRB with guanethidine with stellate ganglion blocks in people with severe RSD following peripheral nerve injury of the upper limb</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2012-09-26 07:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>Conflicts of interest not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Carroll-2009">
<CHAR_METHODS MODIFIED="2012-09-26 13:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>RCT cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 9</P>
<P>Age mean (range) 49.4 (38-67)</P>
<P>Sex: 1 male</P>
<P>Lower limb CRPS-I, with duration of pain of at least 6 months, spontaneous pain rating &gt; 6/10, unsuccessful therapy with at least 2 non-opioid medications (for neuropathic pain), at least a 50% reduction in pain for &gt; 5 h but &lt; 2 weeks from a previous lumbar sympathetic injection</P>
<P>Inciting events: tarsal tunnel surgery n = 1, bunionectomy/cast n = 1,  crush injury n = 1, plantar fasciectomy n = 1, foreign body removal n = 1, ankle arthroscopy n = 1, ankle fracture/cast n = 1, metatarsal fracture n = 1, back surgery n = 1</P>
<P>Diagnostic criteria: IASP (<LINK REF="REF-Merskey-1994" TYPE="REFERENCE">Merskey 1994</LINK>)</P>
<P>Medico-legal factors: not reported</P>
<P>Mean duration of pain (range): 3.8 years (2-14)</P>
<P>Baseline mean pain levels, 10 cm VAS (range): 7.2 cm (4.7-8.9)</P>
<P>Concomitant treatments: not reported but participants asked not to cease existing therapies, but not to start new therapies during study period</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Lumbar sympathetic blocks:</P>
<P>Anterolateral border of L2 vertebral body, fluoroscopy guided</P>
<P>Active: 10 ml of 0.5% bupivacaine with an added 75 units botulinum toxin A<BR/>Control: 10 ml of 0.5% bupivacaine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Primary outcome: time to analgesic failure (time for pain to return to baseline level)</P>
<P>Daily pain intensity - 10 cm VAS, measured for 7 days prior to first injection and recorded daily until participants reported their pain returned to baseline or 1 month (whichever was longer)</P>
<P>Adverse events reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-09-26 13:55:02 +0100" MODIFIED_BY="[Empty name]">
<P>USA</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-22 09:51:05 +0100" MODIFIED_BY="[Empty name]">
<P>To determine whether adding BTA to lumbar sympathetic blockade increases the duration of analgesia</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Authors declared that they had filed a patent for BTA in sympathetic blocks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Freitas-2013">
<CHAR_METHODS MODIFIED="2016-01-05 08:58:06 +0000" MODIFIED_BY="[Empty name]">
<P>RCT parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 40 (though adverse event reporting implies 20 and no CONSORT flowchart presented). Presume 20 per group.</P>
<P>Age: not reported</P>
<P>Sex: not reported</P>
<P>Lower limb CRPS-I.</P>
<P>Diagnostic criteria: IASP <LINK REF="REF-Bruehl-1999" TYPE="REFERENCE">Bruehl 1999</LINK>
</P>
<P>Duration of pain prior to block: &gt; 6 months</P>
<P>Type of initiating injury: not reported</P>
<P>Concomitant treatments: not reported</P>
<P>Medico-legal factors: excluded if pending litigation</P>
<P>Previous treatment: unresponsive to medication and physiotherapy (such as oral gabapentin 2400 mg/d, oral amitriptyline 100 mg/d, and oral carbamazepine 1000 mg/d and physiotherapy for more than 6 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Group 1: LASB lumbar plexus sympathetic block L2-3 and L3-4. 15 ml lidocaine and 100 mcg clonidine at each level</P>
<P>Group 2. Pulsed radiofrequency (PRF) lumbar plexus L2-3 and L3-4, x3 120sec cycles at each level at 42º C. 1 ml of 2% lidocaine injected at each level</P>
<P>Evaluation of technical adequacy of blocks: no</P>
<P>Number of blocks: 1 per site, on 1 occasion</P>
<P>Concomitant treatments: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity VAS, neuropathic pain scale. No numerical data provided.</P>
<P>SF-36. Means reported but no measures of variance</P>
<P>Statistically significant difference seen in "hot pain" at "final score" but this time point is not clearly defined - likely 6 months.</P>
<P>Adverse events: "2 out of 10" had paraesthesia following PRF. "1 out of 10" had paraesthesia following LASB. Note; this implies 20 rather than 40 participants.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-05 10:07:37 +0000" MODIFIED_BY="[Empty name]">
<P>Brazil</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To determine whether percutaneous PRF applied directly to the sympathetic lumbar plexus was more effective than lumbar sympathetic blocks, and, if so, whether this could be achieved without the risks associated with traditional ablative procedures</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-01-05 10:08:53 +0000" MODIFIED_BY="[Empty name]">
<P>Conflicts of interest not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Lim-2007">
<CHAR_METHODS MODIFIED="2016-01-06 09:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 38</P>
<P>Mean age (SD):</P>
<P>Group 1: 61.4 years (10.1)</P>
<P>Group 2. 58.7 years (12.1)</P>
<P>Sex: 21 female, 17 male</P>
<P>Upper Limb CRPS poststroke</P>
<P>Diagnostic criteria: unclear though described a "three phase bone scan test"</P>
<P>Duration of symptoms: not reported</P>
<P>Type of initiating injury: stroke.</P>
<P>Concomitant treatment: conservative physical therapy including passive joint movements</P>
<P>Medico-legal factors: not reported</P>
<P>Previous treatment: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>Group 1: LASB stellate ganglion, lidocaine</P>
<P>Dosage: 10 ml 0.5% lidocaine</P>
<P>Number of blocks: 5 blocks: 1 every 3 days for 15 days</P>
<P>Evaluation of technical adequacy of block: not reported</P>
<P>Group 2: oral corticosteroids for 14 days. 60 mg of oral prednisolone was administered in two 30mg doses depending on the hormone cortisol rhythm on days 1-3, and applied 40 mg on days 4-6, 30 mg on days 7-9, and 20 mg on days 10-12. Single dose of 10 mg was administered on days 13-14. Oral administration was stopped after 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>0-3 scale hand pain with passive movement or palpation. Measured at 15 and 30 days from start of treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-06 09:10:48 +0000" MODIFIED_BY="[Empty name]">
<P>Korea</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To compare the therapeutic effects between stellate ganglion block and steroid therapy in poststroke complex regional pain syndrome</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Nascimento-2010">
<CHAR_METHODS MODIFIED="2012-09-26 09:40:21 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 43</P>
<P>Mean age (range):</P>
<P>Group 1: 37.7 years (27-54)</P>
<P>Group 2: 38.6 years (25-50)</P>
<P>Group 3: 39.0 years (27-50)</P>
<P>Sex:</P>
<P>Group 1 (n = 14): 1 male</P>
<P>Group 2 (n = 15): 1 male</P>
<P>Group 3 (n = 14): 1 male</P>
<P>Upper extremity CRPS-I</P>
<P>Diagnostic criteria: IASP (<LINK REF="REF-Merskey-1994" TYPE="REFERENCE">Merskey 1994</LINK>)</P>
<P>Mean duration of pain (range):</P>
<P>Group 1: 24.2 months (3-72)</P>
<P>Group 2: 24.2 months (8-72)</P>
<P>Group 3: 22.3 months (2-48)</P>
<P>Mean baseline pain intensity (SE), 10 cm VAS scale:</P>
<P>Group 1: 8.7 cm (0.3)</P>
<P>Group 2: 8.7 cm (0.3)</P>
<P>Group 3: 8.3 cm (0.3)</P>
<P>Inciting event:</P>
<P>Repetitive strain injury n = 18, carpal tunnel syndrome n = 11, late postsurgical pain n = 8, fracture and long-lasting immobilisation n = 3, stab wound n = 2, unknown n = 1</P>
<P>Previous treatment for CRPS: unsuccessful use of tricyclic antidepressants, gabapentin, opioids or anti-convulsants</P>
<P>At admission all free of drugs.</P>
<P>Medico-legal factors: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Group 1: SGB, anterior paratracheal approach, fluoroscopy-guided, 70 mg 1% lidocaine</P>
<P>Group 2: SGB, identical approach,70 mg 1% lidocaine + 30 &#956;g clonidine</P>
<P>Group 3: IVRB 7.0 ml solution 1% lidocaine with 1 &#956;g/kg clonidine. Tourniquet pressure released 30 min later.</P>
<P>Evaluation of adequacy of block? yes, temperature checked</P>
<P>No. of blocks: 5, x 1 weekly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity 0-10 cm VAS (anchors "no pain" to "worst pain imaginable")</P>
<P>Pain was measured immediately before and soon after the end of each procedure. Pain intensity scored daily. Pain measured one week after the last procedure.</P>
<P>Duration of analgesia calculated as the interval between the end of the procedure and the time at which VAS &#8805; 3 was recorded.</P>
<P>Adverse events reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-09-26 09:40:34 +0100" MODIFIED_BY="[Empty name]">
<P>Brazil</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To compare the efficacy of IVRB produced by combining lidocaine with clonidine, to that of SGB produced by the injection of lidocaine, alone or combined with clonidine, into the stellate ganglion, for the management of pain in people with upper extremity CRPS-I</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Price-1998">
<CHAR_METHODS MODIFIED="2013-07-22 10:22:17 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised controlled trial (cross-over)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 7 (3 lower extremity, 4 upper extremity pain)</P>
<P>Mean age: 42 years (SD 11; range: 32-52)</P>
<P>Sex: 3 male</P>
<P>CRPS-I or -II of upper or lower extremities (excluded if CRPS in multiple areas)</P>
<P>Diagnostic criteria: IASP (<LINK REF="REF-Merskey-1994" TYPE="REFERENCE">Merskey 1994</LINK>)</P>
<P>Mean duration of symptoms: 3 years (SD 2 years; range 18 months to 7 years)</P>
<P>Inciting event: trauma (n = 6), surgical (n = 1)</P>
<P>Medico-legal factors: not reported</P>
<P>Previous treatment: not reported</P>
<P>Concomitant treatment: all participants continued concomitant physical therapy and medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Active condition:</P>
<P>SGB with lidocaine (15 ml of lidocaine 1%)</P>
<P>Lumbar sympathetic blockade with 15 ml 1% lidocaine (test solution) followed by 10 ml bupivacaine 0.125%</P>
<P>Evaluation of technical adequacy of block? yes - evaluated Horner's syndrome and surface skin temperature for stellate ganglion blocks. Nothing reported for lumbar blocks.<BR/>
</P>
<P>Control condition:</P>
<P>Stellate ganglion: 15 ml saline</P>
<P>Lumbar: 15 ml saline + 10 ml saline</P>
<P>The blocks were separated by a period of 7-10 days</P>
<P>Number of blocks: 1 for each condition<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity and pain unpleasantness (0-10 VAS)</P>
<P>Pain outcomes measured every 15 min for 1.5 h prior to injection and every 15 min for 1 h following injection. Pain outcomes then rated 4 times a day (morning, midday, afternoon, evening) for 7 days postinjection</P>
<P>Time to peak analgesia measured as the VAS unit difference between pre-injection baseline pain rating and the lowest VAS rating in the first hour</P>
<P>Duration of pain relief measured as the time it took for pain intensity to return to 50% of the difference between baseline and peak analgesic effect<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-09-26 11:48:33 +0100" MODIFIED_BY="[Empty name]">
<P>USA</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-22 10:26:28 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the diagnostic and therapeutic value of local anaesthetic sympathetic blocks</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Author confirmed the quasi-random allocation in correspondence; adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Rocha-2014">
<CHAR_METHODS MODIFIED="2016-01-06 09:39:07 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 36</P>
<P>Mean age (SD):</P>
<P>Group 1 : 42 years (13.5)</P>
<P>Group 2 : 44.4 years (8.9)</P>
<P>Sex: 19 female, 17 male</P>
<P>Upper limb CRPS</P>
<P>Diagnostic criteria: IASP (<LINK REF="REF-Merskey-1994" TYPE="REFERENCE">Merskey 1994</LINK>) then switched to IASP (<LINK REF="REF-Harden-2010" TYPE="REFERENCE">Harden 2010</LINK>). Participants screened under old criteria were then excluded.</P>
<P>Duration of symptoms (months):</P>
<P>Group 1: 22.7 (26.3)</P>
<P>Group 2: 21.0 (2.16)</P>
<P>Type of initiating injury: mixed: fractures, contusions, surgery, work-related</P>
<P>Concomitant treatments: unclear</P>
<P>Previous treatment: 4 week standardised multimodal protocol including physical therapy, oral analgesic polytherapy: antidepressants, analgesics, opioids, gabapentin and psychological input.</P>
<P>Medico-legal factors: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Group 1: LASB T2 sympathetic ganglion (fluoroscopically guided)</P>
<P>Group 2: subcutaneous space injection of same agents (fluoroscopy also used)</P>
<P>Agents: 10 ml anaesthetic + steroid. 5 ml 75% ropivacaine, 5 ml triamcinolone</P>
<P>Evaluation of technical adequacy of block: yes - measurement of arm temperature</P>
<P>Number of blocks: 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Average pain score from Brief Pain Inventory</P>
<P>McGill Pain Questionnaire</P>
<P>Adverse events</P>
<P>1 month and 1 year follow-up</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-06 09:39:17 +0000" MODIFIED_BY="[Empty name]">
<P>Brazil</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To evaluate the efficacy of TSB for upper limb CRPS-I</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Authors declare no conflict of interest</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Rodriguez-2005">
<CHAR_METHODS MODIFIED="2013-07-22 10:37:10 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>N= 82</P>
<P>Mean age (no SDs provided):</P>
<P>Group 1: 44.1 years</P>
<P>Group 2: 46.1 years,</P>
<P>Sex:</P>
<P>Group 1: 36.6% male</P>
<P>Group 2: 46.3% male</P>
<P>Upper limb CRPS (type I or type II) with presence of pain mediated by the sympathetic nervous system (defined as a decrease in resting pain by 50% with a stellate ganglion block)</P>
<P>Diagnostic criteria: IASP (<LINK REF="REF-Merskey-1994" TYPE="REFERENCE">Merskey 1994</LINK>; <LINK REF="REF-Reinders-2002" TYPE="REFERENCE">Reinders 2002</LINK>)</P>
<P>Inciting event: </P>
<P>71.4% of CRPS cases were secondary to accidental or violent trauma and 18% occurred following surgical procedures.</P>
<P>Mean duration of symptoms (no SDs provided):</P>
<P>Group 1: 253.7 days</P>
<P>Group 2: 213.4 days</P>
<P>Medico-legal factors:</P>
<P>Group 1: 14.6% had a compensation claim</P>
<P>Group 2: 24.4% had a compensation claim</P>
<P>Previous treatment: participants were excluded if they had previous stellate ganglion blocks; no other previous treatment reported</P>
<P>Concomitant treatment: Group 1 also received physical therapy and pharmacological treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P> </P>
<P>Group 1: SGB, physical therapy and pharmacological treatment</P>
<P>Site of block: paratracheal at the height of the cricoid cartilage</P>
<P>Number of blocks: 5</P>
<P>Type of substance injected: 10 cc of volume with equal parts of 2% lidocaine and 0.5% bupivacaine</P>
<P>Evaluation of technical adequacy: increase in temperature of at least 1° C of the hand and face (affected side) and the presence of Horner's syndrome (ptosis of the upper eye lid and conjunctivitis)</P>
<P>Group 2: Physical therapy and pharmacological treatment only(Control group):</P>
<P>Received physical therapy and pharmacological treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity (VAS). Measured at baseline, 1 month and 2 months. Exact follow-up time appears to be variable among participants (i.e. followed for more than 2 months in some).</P>
<P>Therapeuctic efficacy: number of participants with at least 50% reduction in the pain. Measured at 2 months postintervention.</P>
<P>Efficacy: (incidence of pain in control group &#8722; incidence of pain in the SGB group)/incidence of pain in the control group * 100</P>
<P>Absolute risk reduction (incidence of pain in control group &#8722; incidence of pain in the intervention group). Measured at 2 months postintervention.</P>
<P>NNTB = 1/ARR (calculated at 2 months postintervention)</P>
<P>Relapse (return of pain to less than 50% reduction or return of pain to baseline levels or above); determined at 2 months postintervention</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-02-02 21:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Colombia</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To determine the analgesic efficacy of the stellate ganglion blockade (SGB) in the alleviation of pain mediated by the sympathetic nervous system in patients with Complex Regional Pain Syndrome</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>This is the first published study by Rodriguez. There are 2 other published studies and one IASP abstract that use an identical study design. It is unclear if all the studies represent the same cohort. We attempted to contact the authors 3 times with no success.</P>
<P>This study was translated and interpreted by a researcher fluent in Spanish. The study author, TS, worked with the researcher to fully interpret and score.</P>
<P>Funded by Colciencias and the Universidad Libre Seccional Cali. No conflict of interest stated. No adverse events reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Toshniwal-2012">
<CHAR_METHODS MODIFIED="2013-07-22 10:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N= 33</P>
<P>Mean age (SD):</P>
<P>Group 1: 44.33 years (13.6)</P>
<P>Group 2: mean age 42 years (16.6)</P>
<P>Sex:</P>
<P>Group 1 (n=19): 6 male</P>
<P>Group 2 (n=14): 7 male</P>
<P>CRPS-I of the upper extremity which had lasted at least 3 months and was refractory to medical management. People receiving any interventional procedure for the condition were excluded.</P>
<P>Diagnostic criteria: <LINK REF="REF-Bruehl-1999" TYPE="REFERENCE">Bruehl 1999</LINK> ), </P>
<P>Mean duration of pain (SD):</P>
<P>Group 1: 8.8 months (4.4).</P>
<P>Group 2: 9.3 months (SD 2.8)</P>
<P>Inciting event: not reported</P>
<P>Medico-legal factors: not reported</P>
<P>Previous treatment: not reported</P>
<P>Concomitant treatment: physiotherapy (4 weeks), no change in medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Continuous stellate ganglion block (CSG) versus continuous infraclavicular brachial plexus block (CIBP). Both groups received physiotherapy (as per recommendations from same physiotherapist) for 4 weeks. No change in regular medications in either group.</P>
<P>Group 1: CSG block</P>
<P>Site: stellate ganglion - 20 gauge IV cannula was inserted anterolaterally into the neck, lateral to the cricoid cartilage. Cannula inserted until the C6 tubercle was hit at which time the stylet was removed and the cannula vertically sutured to the skin. Cannula position confirmed via injection of 2 ml of radio-opaque dye under fluoroscopy</P>
<P>Number of blocks: continuous block for 7 days</P>
<P>Type/amount of anaesthetic: bolus of 10 ml (5 + 5 ml) 0.25% bupivacaine was injected. An elastomeric pump (solution of 0.125% bupivacaine 280 ml, delivering at 2 ml/h) was attached to the catheter. Pump was changed on day 5.</P>
<P>Evaluation of technical adequacy: measured temperature difference between arms (&gt; 1.5° C temperature increase in the affected arm considered adequate sympatholysis) and degree of vasodilatation using plethysmography scores (where an increase in the waveform reading score by 2 was considered improved circulation secondary to sympatholysis/vasodilatation).</P>
<P>Group 2: CIBP block</P>
<P>Site: brachial plexus - identified using nerve stimulation by vertical approach and inserting a Contiplex D needle with catheter Position was confirmed via injection of 3 cc of radio-opaque dye under fluoroscopy</P>
<P>Number of block: continuous block for 7 days</P>
<P>Type/amount of anaesthetic: bolus of 30 ml 0.25% bupivacaine was injected through the catheter. An elastomeric pump containing 0.125% bupivacaine 400 ml delivering at 5 ml/h was connected to the catheter. Pump was changed on days 3 and 6.</P>
<P>Evaluation of technical adequacy: As above. Both groups had an increase in temperature of the blocked arm (vs contralateral hand) and improvement in circulation (at 30 min); no difference between groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Neuropathic pain scale - components analysed separately (intensity, sharp, hot, dull, cold, sensitive, itchy, unpleasant, deep pain, surface pain, and quality of pain). Scale was 0 (i.e., intensity, 0 = no pain) to 10 (i.e., intensity, 10 = most intense pain sensation imaginable).</P>
<P>Measured at 6 min, 30 min, 2 h, 12 h, and 24 h, day 2, day 3, day 4, day 5, day 6, day 7, week 2, week 3, week 4</P>
<P>Adverse events reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-07-10 02:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>USA</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To compare the efficacy of continuous stellate ganglion (CSG) block with that of continuous infraclavicular brachial plexus (CIBP) block in management of CRPS type I of upper extremity</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2013-07-22 11:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>The authors acknowledged editorial support from 2 doctors from Wayne State University, Detroit. The authors declared that they have nothing to disclose and no conflict of interest.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Yoo-2012">
<CHAR_METHODS MODIFIED="2016-01-05 10:56:13 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 42</P>
<P>Mean age (SD):</P>
<P>Group 1: 61.3 years (5.6)</P>
<P>Group 2: 59.1 years (4.5)</P>
<P>Sex: 25 males, 20 females (note: likely error as not consistent with overall N)</P>
<P>CRPS poststroke, upper limb</P>
<P>Type of initiating injury: stroke</P>
<P>Diagnostic criteria: IASP <LINK REF="REF-Harden-2010" TYPE="REFERENCE">Harden 2010</LINK>
</P>
<P>Duration of symptoms - "duration since stroke".</P>
<P>Group 1: 2.8 months (1.1) </P>
<P>Group 2: 2.3 months (0.9)</P>
<P>Previous treatment: not reported</P>
<P>Concomitant treatments: not reported</P>
<P>Medico-legal factors: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Group 1: stellate ganglion block without ultrasound guidance. 10 ml lidocaine injection</P>
<P>Group 2: stellate ganglion block with ultrasound guidance. 5 ml lidocaine injection</P>
<P>Number of blocks: 2, 1 week apart</P>
<P>Evaluation of technical adequacy of block: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity VAS, 0-10, anchors "no pain" and "the highest pain"</P>
<P>2- and 4-week follow-up</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-01-05 11:15:00 +0000" MODIFIED_BY="[Empty name]">
<P>Korea</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>To evaluate the effectiveness of ultrasound-guided SGB by comparing with the blind SGB in poststroke CRPS patients in reducing pain and swelling of the affected limb</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Conflict of interest not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Zeng-2003">
<CHAR_METHODS MODIFIED="2013-07-22 11:33:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 60</P>
<P>Age range: 38-71</P>
<P>Sex: 42 males</P>
<P>Shoulder-hand syndrome following stroke</P>
<P>Diagnostic criteria not reported</P>
<P>Duration of symptoms; described as "in the early stages of SHS complicated with paralysis"</P>
<P>Previous treatment not specified</P>
<P>Mean baseline pain, 0-10 VRS (SD):</P>
<P>SGB + rehab group: 6.95 (3.24)</P>
<P>Rehab-only group: 6.85 (3.24)</P>
<P>Medico-legal factors: not reported</P>
<P>Concomitant treatments: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Stellate ganglion block + rehabilitation versus rehabilitation only</P>
<P>SGB: anterior entry, transverse process of C7, agent, dose not reported</P>
<P>Rehabiliation details: reports "comprehensive treatment" eliminating causes of oedema, avoid weight loading of limb, avoid limb trauma, remove factors causing shoulder pain, movement exercises, joint mobilisations, ice therapy, physical therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain VAS (0 = no pain, 2 = little pain, 4 = frequent mild pain or occasional severe pain, 6 = severe pain but tolerable, 8 = continuous pain and intolerable, 10 = severe pain that couldn't be touched).</P>
<P>Pain was measured before treatment, at 10 days and 20 days post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2012-09-26 11:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>China</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-07-22 11:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>Effect of stellate ganglion is observed on base of comprehensive rehabilitation treatment (sic)</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>No statement of financial support or conflict of interest; adverse events not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>ARR</B>: absolute risk reduction; <B>BTA</B>: botulinum toxin A; <B>CIBP</B>: continuous infraclavicular brachial plexus block; <B>CRPS</B>: complex regional pain syndrome; <B>CSG</B>: continuous stellate ganglion block; <B>IASP</B>: International Association for the Study of Pain;<B> IV</B>: intravenous; <B>IVRB</B>: intravenous regional blockade; <B>LASB</B>: local anaesthetic sympathetic blockade; <B>NNTB</B>: number needed to treat for an additional beneficial outcome; <B>PRF</B>: pulsed radiofrequency; <B>RCT</B>: randomised controlled trial; <B>RSD</B>: reflex sympathetic dystrophy; <B>SD</B>: standard deviation; <B>SE</B>: standard error; <B>SF-36</B>: 36-item short-form health survey; <B>SGB</B>: stellate ganglion blockade; <B>SMP</B>: sympathetically maintained pain; <B>VAS</B>: visual analogue scale; <B>VRS</B>: verbal report scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Ackerman-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Arias-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Catala-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Sympathetic blockade versus intravenous lidocaine for postherpetic neuralgia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Dellemijn-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Sympathetic blockade versus phentolamine infusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Erickson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Farcot-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Fukusaki-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Nerve blocks (including sympathetic blocks) for cervical radiculopathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Garrido-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-04 09:56:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glynn-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-04 09:56:52 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Hartrick-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-ISRCTN71968956">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-22 09:45:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kastler-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-22 09:45:29 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Linson-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Malmqvist-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Meier-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&lt; 48 h follow-up postblock</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Perrigot-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not a local sympathetic block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Quevedo-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Raja-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&lt; 48 h follow-up postblock</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Schurmann-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Steinbrocker-1953">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Tran-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Sympathetic blockade plus iohexol versus sympathetic blockade plus saline; evaluating the effect of the contrast agent iohexol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Verdugo-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&lt;48 h follow-up postblock</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Wang-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Wehnert-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&lt;48 h follow-up postblock</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Yucel-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Kostadinova-2012">
<CHAR_METHODS MODIFIED="2016-01-05 11:53:21 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 32</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Stellate ganglion block with bupivacaine vs bupivocaine plus neostigmine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-15 07:44:32 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract of protocol only available - authors contacted for further details</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Rodriguez-2006">
<CHAR_METHODS MODIFIED="2016-01-20 09:28:32 +0000" MODIFIED_BY="[Empty name]">
<P>Parellel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 71</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-20 09:29:42 +0000" MODIFIED_BY="[Empty name]">
<P>SGB, physical therapy and pharmacological treatment vs physical therapy and pharmacological treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity VAS 10 cm. Proportion with 50% pain relief 1 month postblock</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-20 09:32:12 +0000" MODIFIED_BY="[Empty name]">
<P>Not clear whether a distinct trial or an extension of <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>. Authors contacted for clarification.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Rodriguez-2008">
<CHAR_METHODS MODIFIED="2016-01-20 09:32:20 +0000" MODIFIED_BY="[Empty name]">
<P>Parellel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>N = 114</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-20 09:32:20 +0000" MODIFIED_BY="[Empty name]">
<P>SGB, physical therapy and pharmacological treatment vs physical therapy and pharmacological treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>Pain intensity VAS 10 cm. Time to relapsing. 6-month follow-up</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-15 07:44:32 +0000" MODIFIED_BY="[Empty name]">
<P>Conference abstract. Not clear whether a distinct trial or an extension of <LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>. Authors contacted for clarification.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NOTES="&lt;p&gt;AE: should this be 'awaiting classification'? How can a judgement be made about whether to include if the paper has not been assessed.&lt;/p&gt;" NOTES_MODIFIED="2016-07-14 15:46:53 +0100" NOTES_MODIFIED_BY="Anna Erskine" STUDY_ID="STD-Salinas-Cerda-1997">
<CHAR_METHODS MODIFIED="2016-06-16 11:34:27 +0100" MODIFIED_BY="Anna Erskine">
<P>Study report not retrievable</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>
<B>RCT</B>: randomised controlled trial; <B>SGB</B>: stellate ganglion blockade; <B>VAS</B>: visual analogue scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-04-12 07:47:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-10 02:17:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Quote: "randomized"</P>
<P>Comment: Method of randomisation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>Quote: "patients were randomly allocated to two groups"</P>
<P>Comment: Method of randomisation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to which injection they received first"</P>
<P>Comment: method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>Quote: "Patients were randomized to either PRF or sympathetic lumbar block according to computer generated random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: no details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>Quote: "randomly assigned to one of three experimental groups"</P>
<P>Comment: method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>Quote: "Four patients received S first with LA block second, and the order was reversed for the remaining 3 patients"</P>
<P>Comment: quasi-random process used, not truly random. Due to cross-over study design and successful blinding, we feel this presents an unclear risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: no details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Quote: "randomized"</P>
<P>Comment: method of randomisation unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Quote: "patients . . . were randomly assigned to receive CSG block or CIBP block using a computer-generated table of random numbers (50 numbers in two columns)"</P>
<P>Comment: likely done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: method of randomisation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 11:36:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Quote: "randomly divided into two groups"</P>
<P>Comment: method of randomisation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Envelope method used to conceal allocation; group assignment generated by an independent person</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-09 05:46:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-23 12:55:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>Comment: no information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: no details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 09:33:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-23 12:56:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Price-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: participants asked to pick an unmarked opaque envelope containing allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Opaque envelopes used; randomly given to each participant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Quote: "Group allocation was concealed in sealed opaque envelopes that were not opened until patient consent had been obtained"</P>
<P>Comment: likely done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-26 11:12:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-09-25 14:06:12 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Quote: "double blind"</P>
<P>Comment: reported that participants and personnel blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-22 09:41:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>Participant blinding not reported. The interventions are likely to be distinguishable. Unsure if participants aware of study hypothesis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>Quote: "All physicians and patients involved in the study were blinded to which injection contained botulinum toxin A. Data were not unblinded for any patient until the study was completed, and no interim analyses were performed"; "in the crossover injection, the patient received an identical injection"</P>
<P>Comment: injections were identical and participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>Comment: Personnel not blinded however, comparison is between two active invasive interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: Personnel not blinded. Non-invasive control qualitatively different to active intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 23:05:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>Not stated that study was blinded nor whether participants were blind to the study hypotheses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>Quote: "Both the patient and the physician administering the sympathetic ganglia injections were blind with regard to the contents of the injecting syringe (S or LA) and with regard to whether skin surface temperature changes or Horner's syndrome occurred"; "The syringe was filled . . . by a third person who maintained the code for the contents of the syringes and the double-blind nature of the study"; "None of the 7 patients reported subjective differences between effects of S and LA blocks within the first hour after block. However, 2 patients correctly determined that they had received S injection because of the shorter duration of relief received."</P>
<P>Comment: blinding completed and blinding success was formally assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: Personnel not blinded however, comparison is between two active invasive interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Quote: "double blind"</P>
<P>Comment: Probably not. Index and control groups are not indistinguishable, and success of blinding was not tested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-22 11:07:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Both active interventions but does not mention blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: Participant blinding not reported. The interventions are likely to be distinguishable, however both were active invasive interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Index and control groups are not indistinguishable and success of blinding was not tested</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Reported that outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-09 05:46:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>Assessor blinding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>Quote: as above</P>
<P>Comment: self reported outcomes and participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>Comment: Participants blinded to group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: Inadequate blinding of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>Quote: "Side effects and effectiveness of treatment were recorded by another author who was unaware of the procedure"</P>
<P>Comment: while side effects and effectiveness were recorded by a blinded assessor, the use of self reported outcome in participants who may not have been blind to the study hypothesis is a possible risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>Outcomes were self rated and participants were blinded to treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: assessor blinded to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>The investigator was reported to be blinded; however, outcomes were self reported and participants were likely not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Outcomes are self rated, thus unclear risk due to uncertainty whether participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: blinding of participants is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Participant-rated outcomes; participants not blinded (as above)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Drop-outs/withdrawals not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>No missing data post-treatment and one-month follow-up. 3 months: 2/10 missing from SGB group, no missing data for IVRB group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>2/9 participants did not complete the study (one due to technical issues related to the block - malpositioning of the needle - and one because outcome forms were not returned). Only 1 participant received BTA first, and this participant dropped out.</P>
<P>Due to complete blinding and use of a cross-over study design, the effect that this drop-out has on the results is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>1 participant in pulsed radiofrequency group dropped out - reasons unclear and unclear whether data missing or excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: no information reported on attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-08 00:15:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>Excluded 2/45 with clear reasons and clear n reported for all graphs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>2/7 participants missed all pain unpleasantness data but pain intensity data complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: 21% attrition at long-term follow-up and imbalanced across groups. No details provided regarding reasons for loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-22 10:48:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Participants that dropped out or underwent surgery were excluded from the analysis. The number of excluded participants per group is not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Quote: "Three patients were dropped from the study. One patient from each group was excluded from the study as their catheters became dislodged during the follow-up period, and one patient in the CIBP group was excluded because he failed to follow up after 2 weeks"</P>
<P>Comment: drop-out rates &lt; 20% (1 group had 1/19 drop out (5.3%) and 1 had 2/14 drop out (14.3%)). Similar reasons for drop-out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: there are anomalies between group numbers in the text and table 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>All prespecified outcomes were adequately reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>All outcomes listed in methods were reported in the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 09:52:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>Full data not presented for the secondary end point (VAS pain scores over time); comparison of within-injection group change over time provided, but comparison of between-injection group differences not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>Pain outcome data are not reported in numerical format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: outcomes adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>Adequately reported results for all prespecified outcomes (from methods section)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-04 21:58:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>Group results for pain unpleasantness scores not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: outcomes reporting adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-04 21:40:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>No pain scores were given and time to relapse was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 11:08:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Reports all outcomes and all between-group differences</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: outcome reporting adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>All prespecified outcomes adequately reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="10">
<NAME>Adequate sample size?</NAME>
<DESCRIPTION>
<P>&lt;50 patients per arm = high risk of bias; 51-199 patients per arm = unclear risk of bias; &#8805;200 patients per arm = low risk of bias</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Group 1, n = 9; group 2, n = 9; group 3, n = 7</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>N = 19; n = 10 stellate ganglion block group, n = 9 regional IV guanethidine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>N = 9</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>N = 40 entered the study but reporting of adverse events suggests 20 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: N = 38</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 10:21:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>n = 45; 15 participants per treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>N = 7</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: N = 36</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>N = 82 (41 in each group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 11:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>n = 18 (CSG), n = 12 (CIBP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: N = 42</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>N = 60 (30 in each group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="11">
<NAME>Adequate duration of follow-up?</NAME>
<DESCRIPTION>
<P>&#8804;2 weeks of follow up= high risk of bias; 2-6 weeks of follow up= unclear risk of bias; &#8805;8 weeks of follow up= low risk of bias</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>One-month follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 09:41:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>Follow-up of 3 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>Quote: "Patients continued to record daily VAS until they reported their pain had returned to baseline or 1 month, whichever was longer"</P>
<P>Comment: Follow-up was observed until pain returned to baseline levels - for some this was only 4 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>6-month follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: 30 days follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 10:21:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>1 week follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 10:28:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>7 days follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: 1-year follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 06:12:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>Follow-up of 2 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-08 18:04:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>4 weeks of follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: follow-up stated at 4 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-22 11:36:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>20 days follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" NO="12">
<NAME>Free of other bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Aydemir-2006">
<DESCRIPTION>
<P>Pain scores were not significantly different between groups at baseline; identical timing of outcome assessment between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:49:29 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Bonelli-1983">
<DESCRIPTION>
<P>At baseline, SGB group had a significantly shorter duration of symptoms than the IVRB guanethidine group (mean (SD): 6.55 (3.94) months versus 17.55 (14.9) months; P &lt; 0.05) and were significantly older (mean (SD): 52.33 (5.04) years versus 42.77 (4.65) years; P &lt; 0.01).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-23 12:44:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carroll-2009">
<DESCRIPTION>
<P>Cross-over study design ensured similarity between groups; participants allowed to continue current medications but could not start new medications.</P>
<P>Quote: "patients were eligible for their crossover injection 1 month after they reported their pain had returned to baseline"</P>
<P>Comment: 1 month washout period observed, after pain had returned to baseline levels</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Freitas-2013">
<DESCRIPTION>
<P>No baseline data presented; no detail given regarding concomitant treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-06 09:09:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lim-2007">
<DESCRIPTION>
<P>Comment: no other bias detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Nascimento-2010">
<DESCRIPTION>
<P>No differences between groups for important prognostic factors, participants not taking any medication at inclusion, outcome assessment timing identical between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Price-1998">
<DESCRIPTION>
<P>Quote: "Medication use and physical therapy were as similar as possible for the time periods following both saline and lidocaine blocks, and medications were not, as a rule, significantly adjusted during the study period."</P>
<P>Comment: also, cross-over study design ensured similarity between groups for important outcomes and outcome assessment at same time periods</P>
<P>Procedures separated by 7- - 10 days. Figures illustrate pain returned to baseline levels prior to next block.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="NO" STUDY_ID="STD-Rocha-2014">
<DESCRIPTION>
<P>Comment: average pain scores at baseline differ by more than 1 point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2005">
<DESCRIPTION>
<P>No baseline data given on pain intensity; unsure if groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Toshniwal-2012">
<DESCRIPTION>
<P>Groups were similar on important prognostic factors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="UNKNOWN" STUDY_ID="STD-Yoo-2012">
<DESCRIPTION>
<P>Comment: no information given on concomitant treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" RESULT="YES" STUDY_ID="STD-Zeng-2003">
<DESCRIPTION>
<P>Quote: "All patients were in early stage of SHS complicated with paralysis"; "there weren't statistical differences at age, sex, rehabilitation kind"</P>
<P>Comments: no difference between groups in age, sex, rehabilitation and duration of symptoms; outcome assessment timing identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="1">
<TITLE MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine">LASB for pain intensity and duration of pain relief in adults with CRPS</TITLE>
<TABLE COLS="5" ROWS="16">
<TR>
<TD ALIGN="LEFT" COLSPAN="5" VALIGN="BOTTOM">
<P>
<B>Patient or population</B>: adults with CRPS</P>
<P>
<B>Setting</B>: secondary care</P>
<P>
<B>Intervention/comparison</B>: LASB vs various comparisons</P>
<P>
<B>Outcome</B>: pain intensity 0-10 (VAS or NRS)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Comparison</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Studies</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>No of participants</B>
<BR/>
<B>(studies)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Result <B>(effect estimates reported where available from study report)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LASB vs placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>; <LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 (2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No significant between-group difference</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861; <B>Moderate</B>
<SUP>a</SUP> </P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Thoracic LASB + steroid vs subcutaneous local anaesthetic+ steroid</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Favours LASB</P>
<P>Mean difference (0-10 scale)</P>
<P>One month &#8722;1.25 (95% CI &#8722;3.2 to 0.7)</P>
<P>One year &#8722;2.39 (95% CI &#8722;4.72 to &#8722;0.06)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>b</SUP> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LASB vs ultrasound block</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No significant between-group difference</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861; <B>Low</B>
<SUP>c</SUP>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LASB vs IVRB guanethidine</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No significant between-group difference</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>b</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LASB lumbar plexus vs pulsed radiofrequency lumbar plexus</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No significant between-group difference</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>b</SUP>
</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB (lidocaine + clonidine) vs IVRB (lidocaine + clonidine)</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>43 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>No significant between-group difference</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>b</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB + PT+ pharmacological vs PT + pharmacological</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>82 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>Favours SGB group</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>b</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB + PT vs PT</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>60 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>No significant between-group difference</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>b</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Continuous LASB vs continuous brachial plexus block</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>33 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>Favours brachial plexus block</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861; <B>Low</B>
<SUP>c</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Image-guided LASB vs nonimage-guided LASB</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>42 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>Mean difference</P>
<P>2 weeks postinjection &#8722;0.58 (95% CI &#8722;1.51 to 0.35)</P>
<P>4 weeks postinjection &#8722;0.74 (95% CI &#8722;1.36 to &#8722;0.12)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8861;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>d</SUP>
</P>
</TD>
</TR>
<TR>
<TH COLSPAN="5">
<P>
<B>Outcome: hand pain 0-3 scale</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs oral corticosteroids</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>38 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>15 day follow-up, no significant between-group difference at</P>
<P>30 day follow-up 0.4 (95% CI &#8722;0.69 to &#8722;0.11), favours LASB with steroid</P>
</TD>
<TD VALIGN="TOP">
<P>&#8861;&#8861;&#8861;&#8861; <B>Very low</B>
<SUP>d</SUP> </P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="5" VALIGN="TOP">
<P>Outcome: duration of pain relief</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB bupivacaine + BTA vs LASB bupivacaine</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>9 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>Increased duration of relief with BTA</P>
<P>Median time to analgesic failure (days):</P>
<P>LASB bupivacaine + BTA 71 (95% CI 12 to 253)</P>
<P>LASB bupivacaine 10 (95%CI 0 to 12)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861; <B>Low</B>
<SUP>c</SUP>
</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP> Downgraded once for imprecision.<BR/>
<SUP>b</SUP> Downgraded three times for limitations, inconsistency, and imprecision.<BR/>
<SUP>c</SUP>Downgraded twice for inconsistency and imprecision.<BR/>
<SUP>d</SUP>Downgraded four times for limitations, inconsistency, indirectness, and imprecision.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="1">
<TITLE MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">Budapest criteria: diagnostic criteria for complex regional pain syndrome</TITLE>
<TABLE COLS="1" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>To make the <I>clinical </I>diagnosis, the following criteria must be met:</B>
</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1. Continuing pain, which is disproportionate to any inciting event</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2. Must report at least one symptom in <I>three of the four  </I>following categories.</P>
<UL>
<LI>
<B>Sensory: r</B>eports of hyperaesthesia, allodynia, or both.</LI>
<LI>
<B>Vasomotor: </B>reports of temperature asymmetry, skin colour changes, skin colour asymmetry, or a combination of these.</LI>
<LI>
<B>Sudomotor</B>/<B>oedema: </B>reports of oedema, sweating changes, sweating asymmetry, or a combination of these.</LI>
<LI>
<B>Motor</B>/<B>trophic: </B>reports of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic change (hair, nail, skin), or a combination of these.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3. Must display at least one sign <B>at time of evaluation </B>in <I>two or more </I>of the following categories:</P>
<UL>
<LI>
<B>Sensory: </B>evidence of hyperalgesia (to pinprick), allodynia (to light touch, temperature sensation, deep somatic pressure, or joint movement), or both</LI>
<LI>
<B>Vasomotor: </B>evidence of temperature asymmetry (&gt; 1° C), skin colour changes, asymmetry, or a combination of these.</LI>
<LI>
<B>Sudomotor</B>/<B>oedema: </B>evidence of oedema, sweating changes, sweating asymmetry, or a combination of these.</LI>
<LI>
<B>Motor</B>/<B>t</B>
<B>rophic: </B>evidence of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin), or a combination of these.</LI>
</UL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4. There is no other diagnosis that better explains the signs and symptoms</P>
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>For research purposes, diagnostic decision rule should be at least one symptom in all four symptom categories and at least one sign (observed at evaluation) in two or more sign categories. A sign is counted only if it is observed at time of diagnosis.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-02-15 08:54:37 +0000" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2016-07-14 15:49:31 +0100" MODIFIED_BY="Anna Erskine">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>#Study flow diagram for updated searches</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAgkAAAORCAYAAAB4IDFiAAB3f0lEQVR42uydf2SX3R//P+SWJIkk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-07-14 15:49:31 +0100" MODIFIED_BY="Anna Erskine" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYkAAAK9CAIAAABevAfMAAAxLklEQVR42u2dwU4kyRGGS0JCHDhw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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-07-14 15:49:31 +0100" MODIFIED_BY="Anna Erskine" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEyCAMAAAAcIS4IAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<APPENDIX ID="APP-01" MODIFIED="2016-06-20 12:12:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-07-08 00:43:20 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-08 00:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>#1           MeSH descriptor: [Complex Regional Pain Syndromes] explode all trees</P>
<P>#2           complex regional pain syndrome</P>
<P>#3           reflex sympathetic dystrophy</P>
<P>#4           reflex neurovascular dystrophy</P>
<P>#5           (RSD or RND)</P>
<P>#6           shoulder hand syndrome</P>
<P>#7           algoneurodystrophy</P>
<P>#8           algodystrophy</P>
<P>#9           sudeck*</P>
<P>#10         causalgia</P>
<P>#11         (sympathetic* near/3 pain*)</P>
<P>#12         SMP</P>
<P>#13         ((posttraumatic or post-traumatic) next dystrophy)</P>
<P>#14         neuralgia</P>
<P>#15         MeSH descriptor: [Neuralgia] explode all trees</P>
<P>#16         #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15</P>
<P>#17         MeSH descriptor: [Sympatholytics] explode all trees</P>
<P>#18         MeSH descriptor: [Nerve Block] explode all trees</P>
<P>#19         MeSH descriptor: [Anesthetics, Local] explode all trees</P>
<P>#20         bupivacaine</P>
<P>#21         lidocaine</P>
<P>#22         guanethidine</P>
<P>#23         (nerve* near/5 block*)</P>
<P>#24         (stellate near/5 block*)</P>
<P>#25         (sympathetic* near/5 block*)</P>
<P>#26         sympatholytic*</P>
<P>#27         (local near/5 (anaesthetic* or anesthetic*))</P>
<P>#28         #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27</P>
<P>#29         #16 and #28</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-06-20 12:12:23 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-07-31 13:07:53 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-16 23:33:08 +0000" MODIFIED_BY="[Empty name]">
<P>1   exp Complex Regional Pain Syndromes/</P>
<P>2   complex regional pain syndrome.mp.</P>
<P>3   CRPS.mp. </P>
<P>4   reflex sympathetic dystrophy.mp.</P>
<P>5   reflex neurovascular dystrophy.mp.</P>
<P>6   (RSD or RND).mp. </P>
<P>7   shoulder hand syndrome.mp.</P>
<P>8   algoneurodystrophy.mp.</P>
<P>9   algodystrophy.mp.</P>
<P>10 sudeck*.mp.</P>
<P>11 causalgia.mp.</P>
<P>12 (sympathetic* adj3 pain*).mp.</P>
<P>13 SMP.mp.</P>
<P>14 ((posttraumatic or post-traumatic) adj dystrophy).mp.</P>
<P>15 neuralgia.mp. or exp Neuralgia/</P>
<P>16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15</P>
<P>17 exp Sympatholytics/</P>
<P>18 exp Nerve Block/</P>
<P>19 exp Anesthetics, Local/</P>
<P>20 bupivacaine.mp.</P>
<P>21 lidocaine.mp.</P>
<P>22 guanethidine.mp.</P>
<P>23 (nerve* adj5 block*).mp.</P>
<P>24 (stellate adj5 block*).mp.</P>
<P>25 (sympathetic* adj5 block*).mp.</P>
<P>26 sympatholytic*.mp.</P>
<P>27 (local adj5 (anaesthetic* or anesthetic*)).mp.</P>
<P>28 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27</P>
<P>29 16 and 28</P>
<P>30 randomized controlled trial.pt.</P>
<P>31 controlled clinical trial.pt.</P>
<P>32 randomized.ab.</P>
<P>33 placebo.ab.</P>
<P>34 drug therapy.fs.</P>
<P>35 randomly.ab.</P>
<P>36 trial.ab.</P>
<P>37 groups.ab.</P>
<P>38 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37</P>
<P>39 29 and 38</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine" NO="3">
<TITLE MODIFIED="2013-07-08 00:44:07 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-03-31 11:48:58 +0100" MODIFIED_BY="Anna Erskine">
<P>1     exp Complex Regional Pain Syndromes/ </P>
<P>2     complex regional pain syndrome.mp. </P>
<P>3     CRPS.mp. </P>
<P>4     reflex sympathetic dystrophy.mp. </P>
<P>5     reflex neurovascular dystrophy.mp. </P>
<P>6     (RSD or RND).mp. </P>
<P>7     shoulder hand syndrome.mp. </P>
<P>8     algoneurodystrophy.mp. </P>
<P>9     algodystrophy.mp. </P>
<P>10     sudeck*.mp. </P>
<P>11     causalgia.mp. </P>
<P>12     (sympathetic* adj3 pain*).mp. </P>
<P>13     SMP.mp. </P>
<P>14     ((posttraumatic or post-traumatic) adj dystrophy).mp. </P>
<P>15     neuralgia.mp. or exp Neuralgia/ </P>
<P>16     or/1-15 </P>
<P>17     exp Sympatholytics/ </P>
<P>18     exp Nerve Block/ </P>
<P>19     exp Anesthetics, Local/ </P>
<P>20     bupivacaine.mp. </P>
<P>21     lidocaine.mp. </P>
<P>22     guanethidine.mp. </P>
<P>23     (nerve* adj5 block*).mp. </P>
<P>24     (stellate adj5 block*).mp. </P>
<P>25     (sympathetic* adj5 block*).mp. </P>
<P>26     sympatholytic*.mp. </P>
<P>27     (local adj5 (anaesthetic* or anesthetic*)).mp. </P>
<P>28     or/17-27 </P>
<P>29     16 and 28 </P>
<P>30     random$.tw. </P>
<P>31     factorial$.tw. </P>
<P>32     crossover$.tw. </P>
<P>33     cross over$.tw. </P>
<P>34     cross-over$.tw. </P>
<P>35     placebo$.tw. </P>
<P>36     (doubl$ adj blind$).tw. </P>
<P>37     (singl$ adj blind$).tw. </P>
<P>38     assign$.tw. </P>
<P>39     allocat$.tw. </P>
<P>40     volunteer$.tw. </P>
<P>41     Crossover Procedure/ </P>
<P>42     double-blind procedure.tw. </P>
<P>43     Randomized Controlled Trial/ </P>
<P>44     Single Blind Procedure/ </P>
<P>45     or/30-44 </P>
<P>46     (animal/ or nonhuman/) not human/ </P>
<P>47     45 not 46 </P>
<P>48     29 and 47 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-07-08 00:44:58 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-07-08 00:44:40 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-08 00:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>"complex regional pain syndrome" or CRPS or "reflex sympathetic dystrophy" or "reflex neurovascular dystrophy" or RSD or RND or "shoulder hand syndrome" or algoneurodystrophy or algodystrophy or sudeck$ or causalgia or sympathetic pain$ or SMP [Words] and  bupivacaine or lidocaine or guanethidine or (nerve$ block$) or (stellate block$) or (sympathetic$ block$) or sympatholytic$ or (local anaesthetic$) or (local anesthetic$) [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine" NO="5">
<TITLE MODIFIED="2016-01-15 10:57:56 +0000" MODIFIED_BY="[Empty name]">GRADE judgements by comparison</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-14 15:46:53 +0100" MODIFIED_BY="Anna Erskine">
<TABLE COLS="10" ROWS="15">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Comparison</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Studies</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>N for comparison</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Result</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="5" VALIGN="BOTTOM">
<P>
<B>GRADE CRITERIA</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>RATING</B>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>LIMITATIONS</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>INCONSISTENCY</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>INDIRECTNESS</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>IMPRECISION</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>PUBLICATION BIAS</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs placebo</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Price-1998" TYPE="STUDY">Price 1998</LINK>
</P>
<P>
<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Thoracic LASB + steroid vs subcutaneous</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Rocha-2014" TYPE="STUDY">Rocha 2014</LINK>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>1 month &#8211;clinically important difference (not sig).</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1 year clinically important difference (sig)</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs ultrasound block</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Aydemir-2006" TYPE="STUDY">Aydemir 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs IVRB guanethidine</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bonelli-1983" TYPE="STUDY">Bonelli 1983</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs BTA</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carroll-2009" TYPE="STUDY">Carroll 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>Increased duration of relief with BTA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs pulsed radiofrequency</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Freitas-2013" TYPE="STUDY">Freitas 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs oral corticosteroids</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lim-2007" TYPE="STUDY">Lim 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB vs IVRB (both lidocaine + clonidine)</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nascimento-2010" TYPE="STUDY">Nascimento 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB + PT + pharma vs PT + pharma</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rodriguez-2005" TYPE="STUDY">Rodriguez 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>82</P>
</TD>
<TD VALIGN="TOP">
<P>Favours SGB</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LASB+ vs PT</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Zeng-2003" TYPE="STUDY">Zeng 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Continuous LASB vs continuous brachial plexus block</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Toshniwal-2012" TYPE="STUDY">Toshniwal 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>Favours brachial plexus block</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Low</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Image-guided LASB vs nonimage-guided</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yoo-2012" TYPE="STUDY">Yoo 2012</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>No difference</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>X</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>Very low</P>
</TD>
</TR>
</TABLE>
<P>
<B>X</B> = downgrade on this criteria; <B>BTA</B>: botulinum toxin A; <B>IVRB</B>: intravenous regional blockade; <B>LASB</B>: local anaesthetic sympathetic blockade; <B>PT</B>: physical therapy; <B>SGB</B>: stellate ganglion blockades.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_10472083387152902171110602182329_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="10472083387152902171110602182329">
<ADDRESS>
<DEPARTMENT>The Sansom Institute for Health Research, School of Health Sciences</DEPARTMENT>
<ORGANISATION>University of South Australia</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Adelaide</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;4 studies awaiting classification&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies included in the previous update of this review &lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 full-text articles assessed for eligibility &lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;367 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;367 of records after duplicates removed (94 duplicates removed)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;461 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources &lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;361 records excluded &lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 full-text article excluded; not a RCT&lt;/p&gt;&lt;p&gt;1 new study awaiting classification&lt;/p&gt;" WIDTH="211"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;4 studies, previously included, excluded from this update due to inadequate length of follow-up&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>